Professor Andrew Baker

  • Visiting Professor (Institute of Cardiovascular and Medical Sciences)

telephone: 01413301977
email: Andrew.H.Baker@glasgow.ac.uk

Biography

Andrew graduated from the University of London in 1990 with a First Class BSc (Joint Honours) in pharmacology and toxicology and then studied for his PhD with the Leukaemia Research Fund at the University of Wales College of Medicine, graduating in 1994. He then joined the group led by Professor Andrew Newby for his post-doctoral work in Cardiff and developed adenoviral vectors for gene delivery studies in the cardiovascular system. This was at the very early stages of gene therapy. Dr Baker then transferred to a lectureship at the University of Bristol (Bristol Heart Institute) to continue studies on adenovirus-mediated gene transfer to assess vascular function in different model systems. At the same time he initiated his independent research programmes focusing on how to engineer delivery systems for optimal use in vivo in gene therapy applications. In 1999, Dr Baker joined Professor Anna Dominiczak’s group at the University of Glasgow as a Senior Lecturer in Molecular Medicine, then as Reader and now as Professor of Molecular Medicine. He is based at the British Heart Foundation Glasgow Cardiovascular Research Centre (BHF GCRC), which is a translational centre of excellence with a focuc on primary and secondary prevention at cardiovascular disease.

Research interests

Gene therapy aims to harness the power of the genome in a clinical relevant setting, with a focus on diseases with unmet clinical need. For his work on cardiovascular disease, this initially included the generation of replication-defective adenovirus vectors that mediated overexpression of a variety of genes including metalloproteinase inhibitors (TIMPs), inhibitors of matrix degradation in pathological conditions. These vectors were used successfully to inhibit vein graft neointimal thickening in human and pig models. He is currently engaged in research to further develop gene therapy aimed at different aspects of vein graft biology, as well as development of vectors that mediate sustained gene overexpression in vivo.

A second focus has been on the modification of gene delivery systems to try and achieve more efficient and selective delivery of therapeutic agents to cells and tissues relevant to cardiovascular disease. This involves the development of adenoviruses and adeno-associated viruses to both remove their natural cell infection processes and also incorporate new tropism to direct the virus to target cells. This will ultimately lead to a better understanding of the processes that viruses use to achieve infection of mammalian cells as well as improve the safety profile for these viruses for application to human gene therapy. He has recently developed and used vector systems that provide gene delivery to atherosclerotic lesions and cardiac tissue. Armed with these genetic therapy systems his work is now also engaged in the development of gene therapy for cardiac disease as well as for stroke, the latter showing efficiency when combined with stem cell therapy. 

Research:

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • Assessing the contribution of microRNA to in-stent restenosis
    British Heart Foundation
    2015 - 2018
     
  • Gene Therapy For Vein Graft Failure
    Medical Research Council
    2015 - 2019
     
  • Comparison of post stent remodeling & miRNA profiles after bare metal (Gazelle)......
    Biosensors Europe SA
    2015 - 2016
     
  • Adenovirus and coagulation factor interactions and the impact on virus stability and utility for gene therapy
    Biotechnology and Biological Sciences Research Council
    2015 - 2018
     
  • Role of non-coding RNA in vascular pathology
    British Heart Foundation
    2015 - 2019
     
  • BHF Pump Priming Grant: How does the landscape of long non-coding RNA impact upon endothelial differentiation and specification from hES cells?
    British Heart Foundation
    2014 - 2015
     
  • Defining miRNA signatures that regulate pericyte proliferation: a novel approach to develop miRNA-based therapeutic strategies for the treatment of ischaemic complications.
    British Heart Foundation
    2014 - 2016
     
  • Angiotensin-(1-7) and angiotensin-(1-9): assessment as therapeutic targets in acute vascular injury and remodelling.
    Medical Research Council
    2014 - 2017
     
  • Therapeutic manipulation of miR-214
    Medical Research Council
    2014 - 2015
     
  • VascmiR: miRNA in pathological vascular remodelling
    European Research Council
    2014 - 2019
     
  • Targeting microRNA-96 for the treatment of pulmonary arterial hypertension.
    Medical Research Council
    2014 - 2015
     
  • BHF Chair of Translational Cardiovascular Sciences
    British Heart Foundation
    2014 - 2014
     
  • BHF Centre for regenerative medicine
    British Heart Foundation
    2014 - 2017
     
  • Gene Therapy For Vein Graft Failure
    Medical Research Council
    2013 - 2018
     
  • Ad-Vec: Adenovirus Vector Technology: Next Generation Systems for Medical Therapy
    European Commission
    2013 - 2017
     
  • TRANSLATING HUMAN EMBRYONIC STEM CELL-DERIVED ENDOTHELIAL CELL THERAPY TO THE CLINIC
    Medical Research Council
    2013 - 2015
     
  • Development of MiR145 Antagonism as a novel Therapeutic strategy for Application to the treatment of pulmonary arterial hypertension.
    British Heart Foundation
    2013 - 2015
     
  • MicroRNA therapeutics for renal diease.
    Kidney Research UK
    2012 - 2015
     
  • ADENOVIRUS SEROTYPE 49: A NOVEL VECTOR FOR VASCULAR GENE THERAPY
    British Heart Foundation
    2012 - 2015
     
  • ADVANCE - ADenoViruses as novel clinical treatments
    European Commission
    2012 - 2016
     
  • Targeting sensory neurons to restore bone marrow regenerative potential in diabetes
    Medical Research Council
    2012 - 2015
     
  • Role of interleukin-33 (IL-33) and its ST2 receptor in post-ischaemic vascular repair
    British Heart Foundation
    2012 - 2014
     
  • Gender and the development of pulmonary arterial hypertension: regulation of genes from mouse to man
    British Heart Foundation
    2011 - 2014
     
  • Gene Therapy for Vein Graft Failure
    MRC
    2011 - 2016
     
  • Gender and the development of pulmonary arterial hypertension: regulation of genes from mouse to man
    British Heart Foundation
    2011 - 2016
     
  • BHF Chair of Translational Cardiovascular Sciences
    British Heart Foundation
    2011 - 2016
     
  • Evaluation of Mirna and their therapeutic potential in a Mouse Model of In-Stent Restenosis
    British Heart Foundation
    2011 - 2014
     
  • Refinement and assessment of a novel adenovirus targeting platform for application to human gene therapy
    BBSRC
    2011 - 2014
     
  • Improved gene therapy via genetic modification of the adenovirus capsid to ablate interaction with blood coagulation factor X
    BBSRC
    2011 - 2012
     
  • A novel virus for gene therapy
    Royal Society
    2011 - 2016
     
  • Micro RNA and their role in vascular remodelling associated with the development of pulmonary arterial hypertension
    British Heart Foundation
    2011 - 2014
     
  • Red blood cell programme
    Scottish Funding Council
    2011 - 2011
     
  • Red blood cell programme
    Scottish Funding Council
    2011 - 2011
     
  • In vitro and in vivo analysis of stem cell commitment to vascular endothelial cells
    British Heart Foundation
    2011 - 2013
     
  • Clinical translation of endothelial cells derived from human embryonic stem cells
    Technology Strategy Board
    2010 - 2011
     
  • Dissecting the mechanism of action of the novel renin angiotensin hormone angiotensin1-9
    MRC
    2010 - 2013
     
  • Investigating the role of T cells in vascular pathology
    British Heart Foundation
    2010 - 2010
     
  • Interrogation and manipulation of miRNA in acute vascular injury
    British Heart Foundation
    2010 - 2014
     
  • Identification of small molecule inhibitors to block liver uptake and toxicity of adenovirus vectors used for gene therapy
    Scottish Funding Council
    2009 - 2011
     
  • Production of cardiomyocytes from human embryonic stem cells
    Stem Cells for Safer Medicines
    2009 - 2010
     
  • Induced pluripoptent cells: analysis of cell reprogramming of dermal fibroblasts derived from patients with disease vs age-matched healthy controls
    British Heart Foundation
    2009 - 2012
     
  • Interrogation of the adenovirus hexon: A new paradigm for virus biology and application to therapeutic gene delivery
    BBSRC
    2009 - 2012
     
  • Interrogation and manipulation of micro RNA during differentiation of human ES cells to cardiomyocyte and vascular lineages
    British Heart Foundation
    2009 - 2013
     
  • Evaluating the impact of coagulation factors on gene delivery using pseudotyped adenoviruses - receptor usage, bioavailability and toxicology
    BBSRC
    2009 - 2011
     
  • Development of Virus- and Cell-based Targeting Platforms for Renal Gene Therapy
    Myrovlytis Trust
    2009 - 2012
     
  • Investigation into the role of the atypical chemokine receptor D6 in atherosclerosis: murine and human studies
    British Heart Foundation
    2009 - 2012
     
  • BrainCAV
    European Commission
    2008 - 2012
     
  • A combined approach targeting oxidative stress and apoptosis in stroke
    British Heart Foundation
    2008 - 2012
     
  • Optimisation and analysis of integrating and non-integrating lentiviruses for vascular gene transfer in vivo - application to in-stent restenosis with delivery of Nogo-B
    British Heart Foundation
    2008 - 2011
     
  • Genomics and proteomics of hypertension and its vascular complications: the pathwayomic strategies.
    British Heart Foundation
    2008 - 2011
     
  • The role of vitamin K-dependent coagulation zymogens in adenovirus dissemination and pharmacodynamics in vivo.
    Wellcome Trust
    2008 - 2009
     
  • Exploiting plaque-targeted adeno-associated viruses (AAV) to modify plaque biology in apoE-/-mice.
    British Heart Foundation
    2008 - 2009
     
  • The role of endothelial tryptophan hydroxylase in pulmonary vascular remodelling: an integrated approach
    BBSRC
    2008 - 2010
     
  • A new strategy to achieve targeted adenoviral gene delivery in vivo - mechanistic and therapeutic insights
    BBSRC
    2007 - 2011
     
  • Does ACE2 have a protective role in the heart? Systematic analysis of ACE2 in a disease model
    British Heart Foundation
    2007 - 2010
     
  • Evaluating the impact of coagulation factors on gene delivery using pseudotyped adenoviruses - receptor usage, bioavailability and toxicology
    BBSRC
    2007 - 2011
     
  • Capacity Building Award in Integrative Mammalian Biology
    BBSRC
    2007 - 2012
     
  • Optimisation of gene delivery to human saphenous vein for application to clinical trials
    Scottish Executive Health Department
    2007 - 2008
     
  • A novel gene therapy approach to treatment of renal disease
    Kidney Research UK
    2006 - 2008
     
  • Unravelling the effect of cadherin dysregulation in the heart
    Wellcome Trust
    2006 - 2007
     
  • Identification of peptides which target FCoV infected cells
    Morris Animal Foundation
    2005 - 2006
     
  • Evaluation of sustained efficacy of venous bypass graft gene therapy
    British Heart Foundation
    2005 - 2009
     
  • Targeted gene therapy for cardiovascular disease
    MRC
    2005 - 2008
     
  • In vivo targeting of atherosclerotic plaques - a potential for therapeutics and diagnosis
    British Heart Foundation
    2005 - 2009
     
  • Sustained gene delivery in vivo using vascular-targeted AAV vectors
    British Heart Foundation
    2005 - 2008
     
  • High Fidelity Phenotyping combined with genomics, proteomics and metabonomics close to the patient
    British Heart Foundation
    2004 - 2008
     
  • Selective gene delivery to the vasculature using peptide-modified adenoviral vectors
    BBSRC
    2004 - 2007
     
  • CANCERDEG - Extracellular proteases and the cancer degradome : Diagnostic markers, therapeutic targets and tumour imaging agents.
    European Commission
    2004 - 2008
     
  • Development of systemic gene delivery to the kidney
    Kidney Research UK
    2003 - 2005
     
  • Development and evaluation of novel adeno-associated viral vectors for long term gene therapy
    MRC
    2003 - 2006
     
  • Development of a novel adenovirus-based, targetable vector for selective in vivo gene delivery
    British Heart Foundation
    2003 - 2005
     
  • Genetic determinants of hypertension and its vascular complications: from positional candidate genes to vascular gene transfer strategies
    British Heart Foundation
    2003 - 2008
     
  • Targeted delivery of gene-based medicines to vascular endothelium
    BBSRC
    2002 - 2005
     

Additional information

Prizes, Awards and Distinctions

  • 1999: British Cardiac Society - Young Investigator Research Prize for work entitled "Gene therapy for vein grafting: Tissue inhibitor of metalloproteinases-3 (TIMP-3) inhibits neointima formation in vitro and in vivo in part by promoting apoptosis"
  • 1990: Blansford Prize in Pharmacology - Awarded for the best overall perfomance in final year pharmacology degree course

Research Fellowship

  • 2002 - ongoing: American Heart Association Council for High Blood Pressure Research - International Fellowship

Publications

List by: Type | Date

Jump to: 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000
Number of items: 191.

2016

Ballantyne, M.D., McDonald, R.A., and Baker, A.H. (2016) lncRNA/MicroRNA interactions in the vasculature. Clinical Pharmacology and Therapeutics, 99(5), pp. 494-501. (doi:10.1002/cpt.355) (PMID:26910520)

Boulberdaa, M. et al. (2016) A role for the long non-coding RNA SENCR in commitment and function of endothelial cells. Molecular Therapy, 24(5), pp. 978-990. (doi:10.1038/mt.2016.41) (PMID:26898221)

Stevens, H. C., Deng, L., Grant, J. S., Pinel, K., Thomas, M., Morrell, N. W., MacLean, M. R., and Baker, A. (2016) Regulation and function of miR-214 in pulmonary arterial hypertension. Pulmonary Circulation, 6(1), pp. 109-117. (doi:10.1086/685079)

Alonso-Padilla, J., Papp, T., Kaján, G. L., Benkő, M., Havenga, M., Lemckert, A., Harrach, B., and Baker, A. H. (2016) Development of novel adenoviral vectors to overcome challenges observed with HAdV-5 based constructs. Molecular Therapy, (doi:10.1038/mt.2015.194) (PMID:26478249)

2015

Brittan, M., Hunter, A., Boulberdaa, M., Fujisawa, T., Skinner, E. M., Shah, A. S., Baker, A.H., and Mills, N. L. (2015) Impaired vascular function and repair in patients with premature coronary artery disease. European Journal of Preventive Cardiology, 22(12), pp. 1557-1566. (doi:10.1177/2047487315600169) (PMID:26276790)

Deng, L. et al. (2015) MicroRNA-143 activation regulates smooth muscle and endothelial cell crosstalk in pulmonary arterial hypertension. Circulation Research, 117(10), pp. 870-883. (doi:10.1161/CIRCRESAHA.115.306806) (PMID:26311719)

McDonald, R. A., Pinel, K., and Baker, A. H. (2015) Micro(RNA) management of smooth muscle cell phenotype and response to vascular injury. Cardiovascular Research, 107(4), pp. 403-406. (doi:10.1093/cvr/cvv199) (PMID:26224571)

Schneider, M. D., Baker, A. H., and Riley, P. (2015) Hopx and the cardiomyocyte parentage. Molecular Therapy, 23(9), pp. 1420-1422. (doi:10.1038/mt.2015.140) (PMID:26321185)

Wallace, E., Morrell, N. W., Yang, X. D., Long, L., Stevens, H., Nilsen, M., Loughlin, L., Mair, K. M., Baker, A. H., and MacLean, M. R. (2015) A sex-specific microRNA-96/5HT1B Axis influences development of pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine, 191(12), pp. 1432-1442. (doi:10.1164/rccm.201412-2148OC) (PMID:25871906)

McDonald, R. A. et al. (2015) Reducing in-stent restenosis therapeutic manipulation of miRNA in vascular remodeling and inflammation. Journal of the American College of Cardiology, 65(21), pp. 2314-2327. (doi:10.1016/j.jacc.2015.03.549) (PMID:26022821) (PMCID:PMC4444526)

Dakin, R. S., Parker, A. L., Delles, C., Nicklin, S. A., and Baker, A. H. (2015) Efficient transduction of primary vascular cells by the rare adenovirus serotype 49 vector. Human Gene Therapy, 26(5), pp. 312-319. (doi:10.1089/hum.2015.019) (PMID:25760682)

Nicklin, S. A., Griesenbach, U., and Baker, A. H. (2015) Special focus issue on the annual meeting of the british society for gene and cell therapy. Human Gene Therapy, 26(5), pp. 247-248. (doi:10.1089/hum.2015.2500) (PMID:25989311)

Duffy, M., Ma, J., Deng, L., Dakin, R. S., Uil, T., Custers, J., Kelly, S. M., McVey, J. H., Nicklin, S. A., and Baker, A. H. (2015) Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivo. PLoS Pathogens, 11(2), e1004673. (doi:10.1371/journal.ppat.1004673)

2014

Lopez Gordo, E., Denby, L., Nicklin, S. A., and Baker, A. H. (2014) The importance of coagulation factors binding to adenovirus: historical perspectives and implications for gene delivery. Expert Opinion on Drug Delivery, 11(11), pp. 1795-1813. (doi:10.1517/17425247.2014.938637)

White, K. et al. (2014) Endothelial apoptosis in pulmonary hypertension is controlled by a microRNA/programmed cell death 4/caspase-3 axis. Hypertension, 64(1), pp. 185-194. (doi:10.1161/HYPERTENSIONAHA.113.03037)

Coughlan, L., Uusi-Kerttula, H., Ma, J., Degg, B. P., Parker, A. L., and Baker, A. H. (2014) Retargeting adenovirus serotype 48 fiber knob domain by peptide incorporation. Human Gene Therapy, 25(4), pp. 385-394. (doi:10.1089/hum.2014.016) (PMID:24617540)

Baker, A. H. (2014) Adenovirus-based vectors: maximizing opportunities and optimizing a rich diversity of vectors for gene-based therapy. Human Gene Therapy, 25(4), pp. 255-256. (doi:10.1089/hum.2014.2508)

Denby, L. et al. (2014) MicroRNA-214 antagonism protects against renal fibrosis. Journal of the American Society of Nephrology, 25(1), pp. 65-80. (doi:10.1681/ASN.2013010072)

2013

Grant, J. S., Morecroft, I., Dempsie, Y., van Rooij, E., MacLean, M. R., and Baker, A. H. (2013) Transient but not genetic loss of miR-451 attenuates the development of pulmonary arterial hypertension. Pulmonary Circulation, 3(4), pp. 840-850. (doi:10.1086/674751) (PMID:25006399) (PMCID:PMC4070830)

Grant, J. S., White, K., MacLean, M. R., and Baker, A. H. (2013) MicroRNAs in pulmonary arterial remodeling. Cellular and Molecular Life Sciences, 70(23), pp. 4479-4494. (doi:10.1007/s00018-013-1382-5)

Ramdas, V., McBride, M., Denby, L., and Baker, A. H. (2013) Canonical transforming growth factor-β signaling regulates disintegrin metalloprotease expression in experimental renal fibrosis via miR-29. American Journal of Pathology, 183(6), pp. 1885-1896. (doi:10.1016/j.ajpath.2013.08.027)

Scott, E., Loya, K., Mountford, J., Milligan, G., and Baker, A. H. (2013) MicroRNA regulation of endothelial homeostasis and commitment—implications for vascular regeneration strategies using stem cell therapies. Free Radical Biology and Medicine, 64, pp. 52-60. (doi:10.1016/j.freeradbiomed.2013.04.037)

Duffy, M. R., Parker, A. L., Kalkman, E. R., White, K., Kovalskyy, D., Kelly, S. M., and Baker, A. H. (2013) Identification of novel small molecule inhibitors of adenovirus gene transfer using a high throughput screening approach. Journal of Controlled Release, 170(1), pp. 132-140. (doi:10.1016/j.jconrel.2013.05.007)

McDonald, R. A. et al. (2013) miRNA-21 is dysregulated in response to vein grafting in multiple models and genetic ablation in mice attenuates neointima formation. European Heart Journal, 34(22), pp. 1636-1643. (doi:10.1093/eurheartj/eht105)

Baker, A.H., Nicklin, S.A., and Shayakhmetov, D.M. (2013) FX and host defense evasion tactics by adenovirus. Molecular Therapy, 21(6), pp. 1109-1111. (doi:10.1038/mt.2013.100)

McKimmie, C.S. et al. (2013) An analysis of the function and expression of D6 on lymphatic endothelial cells. Blood, 121(18), pp. 3768-3777. (doi:10.1182/blood-2012-04-425314)

Baker, A. H., and Delles, C. (2013) Is microRNA-376c a biomarker or mediator of preeclampsia? Hypertension, 61(4), pp. 767-769. (doi:10.1161/HYPERTENSIONAHA.111.00087)

Bradshaw, A. C., and Baker, A. H. (2013) Gene therapy for cardiovascular disease: perspectives and potential. Vascular Pharmacology, 58(3), pp. 174-181. (doi:10.1016/j.vph.2012.10.008)

Howard, L., Mackenzie, R. M., Pchelintsev, N. A., McBryan, T., McClure, J. D., McBride, M. W., Kane, N. M., Adams, P. D., Milligan, G., and Baker, A. H. (2013) Profiling of transcriptional and epigenetic changes during directed endothelial differentiation of human embryonic stem cells identifies FOXA2 as a marker of early mesoderm commitment. Stem Cell Research and Therapy, 4(2), Art. 36. (doi:10.1186/scrt192)

Kane, N., and Baker, A. (2013) Pluripotent stem cell-derived endothelial cells for vascular disease therapy. International Drug Discovery, (In Press)

Parker, A.L., White, K.M., Lavery, C.A., Custers, J., Waddington, S.N., and Baker, A.H. (2013) Pseudotyping the adenovirus serotype 5 capsid with both the fibre and penton of serotype 35 enhances vascular smooth muscle cell transduction. Gene Therapy, 20(12), pp. 1158-1164. (doi:10.1038/gt.2013.44)

Parker, A. L., Bradshaw, A. C., Alba, R., Nicklin, S. A., and Baker, A. H. (2013) Capsid modification strategies for detargeting adenoviral vectors. In: Chillon, M. and Bosch, A. (eds.) Adenovirus: Methods and Protocols [3rd.]. Series: Methods in molecular biology (1089). Humana Press, pp. 45-59. ISBN 9781627036788 (doi:10.1007/978-1-62703-679-5_3)

Son, D.J. et al. (2013) The atypical mechanosensitive microRNA-712 derived from pre-ribosomal RNA induces endothelial inflammation and atherosclerosis. Nature Communications, 4(3000), (doi:10.1038/ncomms4000)

White, K. M., Alba, R., Parker, A. L., Wright, A. F., Bradshaw, A. C., Delles, C., McDonald, R. A., and Baker, A. H. (2013) Assessment of a novel, capsid-modified adenovirus with an improved vascular gene transfer profile. Journal of Cardiothoracic Surgery, 8(183), (doi:10.1186/1749-8090-8-183)

2012

Bradshaw, A. C., Coughlan, L., Miller, A. M.., Nicklin, S. A., Baker, A. H., Alba, R., and van Rooijen, N. (2012) Biodistribution and inflammatory profiles of novel penton and hexon double-mutant serotype 5 adenoviruses. Journal of Controlled Release, 164(3), pp. 394-402. (doi:10.1016/j.jconrel.2012.05.025)

Miller, A. M., Xu, D., Asquith, D. L., Denby, L., Li, Y., Sattar, N., Baker, A. H., McInnes, I. B., and Liew, F. Y. (2012) IL-33 reduces the development of atherosclerosis (vol 205, pg 339, 2008). Journal of Experimental Medicine, 209(13), p. 2515. (doi:10.1084/jem.2007186820913c)

Coughlan, L. et al. (2012) Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery. Molecular Therapy, 20(12), pp. 2268-2281. (doi:10.1038/mt.2012.162)

Chick, H.E. et al. (2012) Integrase-deficient lentiviral vectors mediate efficient gene transfer to human vascular smooth muscle cells with minimal genotoxic risk. Human Gene Therapy, 23(12), pp. 1247-1257. (doi:10.1089/hum.2012.042)

Kaupisch, A., Kennedy, L., Stelmanis, V., Tye, B., Kane, N.M., Mountford, J.C., Courtney, A., and Baker, A.H. (2012) Derivation of vascular endothelial cells from human embryonic stem cells under GMP-compliant conditions: towards clinical studies in ischaemic disease. Journal of Cardiovascular Translational Research, 5(5), pp. 605-617. (doi:10.1007/s12265-012-9379-2)

Robinson, H. C., and Baker, A. H. (2012) How do microRNAs affect vascular smooth muscle cell biology? Current Opinion in Lipidology, 23(5), pp. 405-411. (doi:10.1097/MOL.0b013e32835719a1)

Robertson, K.E., McDonald, R.A., Oldroyd, K.G., Nicklin, S.A., and Baker, A.H. (2012) Prevention of coronary in-stent restenosis and vein graft failure: Does vascular gene therapy have a role? Pharmacology and Therapeutics, 136(1), pp. 23-34. (doi:10.1016/j.pharmthera.2012.07.002)

Coughlan, L., Vallath, S., Gros, A., Giménez-Alejandre, M., Van Rooijen, N., Thomas, G.J., Baker, A.H., Cascalló, M., Alemany, R., and Hart, I.R. (2012) Combined fiber modifications both to target αvβ6 and detarget the coxsackievirus–adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5. Human Gene Therapy, 23(9), pp. 960-979. (doi:10.1089/hum.2011.218)

Caruso, P. et al. (2012) A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples. Circulation Research, 111(3), pp. 290-300. (doi:10.1161/CIRCRESAHA.112.267591)

Baker, A.H. (2012) Spotlight: Andrew Baker, PhD, FAHA, FESC, FRSE: "A strategy of short-term genetic engineering prevented long-term pathological processes in the vein graft". Circulation, 125(21), F121-F123. (doi:10.1161/CIR.0b013e31825e771f)

Kane, N. M. et al. (2012) Role of MicroRNAs 99b, 181a, and 181b in the differentiation of human embryonic stem cells to vascular endothelial cells. Stem Cells, 30(4), pp. 643-654. (doi:10.1002/stem.1026)

White, K., Kane, N. M., Milligan, G., and Baker, A. H. (2012) The role of miRNA in stem cell pluripotency and commitment to the vascular endothelial lineage. Microcirculation, 19(3), pp. 196-207. (doi:10.1111/j.1549-8719.2012.00161.x)

McDonald, R. A., Hata, A., MacLean, M. R., Morrell, N. W., and Baker, A. H. (2012) MicroRNA and vascular remodelling in acute vascular injury and pulmonary vascular remodelling. Cardiovascular Research, 93(4), pp. 594-604. (doi:10.1093/cvr/cvr299)

Duffy, M. R., Parker, A. L., Bradshaw, A. C., and Baker, A. H. (2012) Manipulation of adenovirus interactions with host factors for gene therapy applications. Nanomedicine, 7(2), pp. 271-288. (doi:10.2217/nnm.11.186)

Alba, R., Bradshaw, A.C., Mestre-Francés, N., Verdier, J.-M., Henaff, D., and Baker, A.H. (2012) Coagulation factor X mediates adenovirus type 5 liver gene transfer in non-human primates (Microcebus murinus). Gene Therapy, 19(1), pp. 109-113. (doi:10.1038/gt.2011.87)

Coughlan, L., Vallath, S., Gros, A., Giménez-Alejandre, M., Van Rooijen, N., Thomas, G.J., Baker, A.H., Cascalló, M., Alemany, R., and Hart, I.R. (2012) Combined fiber modifications both to target αvβ6 and detarget the coxsackievirus–adenovirus receptor improve virus toxicity profilesIn vivobut fail to improve antitumoral efficacy relative to adenovirus serotype 5. Human Gene Therapy, 23(9), pp. 960-979. (doi:10.1089/hum.2011.218)

Duffy, M.R., Kalkman, E., and Baker, A.H. (2012) Identification of a novel small molecule inhibitor of FX-mediated Ad5 gene transfer for gene therapy applications. Molecular Therapy, 20(S1), S117-S117. (doi:10.1038/mt.2012.86)

Flores, M., Graham, D., Dominiczak, A.F., Milligan, G., Baker, A.H., and Nicklin, S.A. (2012) Angiotensin-(1-9) antagonises Angiotensin II-induced cardiac remodeling via the angiotensin type 2 receptor. Proceedings of the Physiological Society, 27, C1.

Flores, M., Graham, D., Dominiczak, A. F., Milligan, G., Baker, A. H., and Nicklin, S. A. (2012) Abstract 231: angiotensin-(1-9) antagonises cardiac remodelling in a mouse model of Angiotensin Ii-induced hypertension. Hypertension, 60, A231.

Morecroft, I., White, K., Caruso, P., Nilsen, M., Loughlin, L., Alba, R., Reynolds, P.N., Danilov, S.M., Baker, A.H., and MacLean, M.R. (2012) Gene therapy by targeted adenovirus-mediated knockdown of pulmonary endothelial Tph1 attenuates hypoxia-induced pulmonary hypertension. Molecular Therapy, 20(8), pp. 1516-1528. (doi:10.1038/mt.2012.70)

Rahim, A.A. et al. (2012) In utero administration of Ad5 and AAV pseudotypes to the fetal brain leads to efficient, widespread and long-term gene expression. Gene Therapy, 19(9), pp. 936-946. (doi:10.1038/gt.2011.157)

2011

Ialenti, A. et al. (2011) Inhibition of in-stent stenosis by oral administration of bindarit in porcine coronary arteries. Arteriosclerosis, Thrombosis and Vascular Biology, 31(11), pp. 2448-2454. (doi:10.1161/ATVBAHA.111.230078)

Howard, L., Kane, N., Milligan, G., and Baker, A. H. (2011) MicroRNAs regulating cell pluripotency and vascular differentiation. Vascular Pharmacology, 55(4), pp. 69-78. (doi:10.1016/j.vph.2011.08.002)

Duffy, M.R., Bradshaw, A.C., Parker, A.L., McVey, J.H., and Baker, A.H. (2011) A cluster of basic amino acids in the factor X serine protease mediate surface attachment of adenovirus/FX complexes. Journal of Virology, 85(20), pp. 10914-10919. (doi:10.1128/JVI.05382-11)

White, K., Loughlin, L., Maqbool, Z., Nilsen, M., McClure, J., Dempsie, Y., Baker, A. H., and MacLean, M. R. (2011) Serotonin transporter, sex, and hypoxia: microarray analysis in the pulmonary arteries of mice identifies genes with relevance to human PAH. Physiological Genomics, 43(8), pp. 417-437. (doi:10.1152/physiolgenomics.00249.2010)

Caporali, A. et al. (2011) Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation, 123(3), pp. 282-291. (doi:10.1161/CIRCULATIONAHA.110.952325)

Kane, N. M., Xiao, Q., Baker, A. H., Luo, Z., Xu, Q., and Emanueli, C. (2011) Pluripotent stem cell differentiation into vascular cells: a novel technology with promises for vascular re(generation). Pharmacology and Therapeutics, 129(1), pp. 29-49. (doi:10.1016/j.pharmthera.2010.10.004)

Baker, A.H. (2011) MicroRNA 21 "Shapes" Vascular Smooth Muscle Behavior Through Regulating Tropomyosin 1. Arteriosclerosis, Thrombosis and Vascular Biology, 31(9), pp. 1941-1942. (doi:10.1161/ATVBAHA.111.231985)

Denby, L. et al. (2011) miR-21 and miR-214 are consistently modulated during renal injury in rodent models. American Journal of Pathology, 179(2), pp. 661-672. (doi:10.1016/j.ajpath.2011.04.021)

George, S. J., Wan, S., Hu, J., McDonald, R.A., Johnson, J. L., and Baker, A.H. (2011) Sustained reduction of vein graft neointima formation by ex vivo TIMP-3 gene therapy. Circulation, 124(11_sup), S135-S142. (doi:10.1161/CIRCULATIONAHA.110.012732)

2010

Burton, P. et al. (2010) Erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) blocks differentiation and maintains the expression of pluripotency markers in human embryonic stem cells. Biochemical Journal, 432(3), pp. 575-584. (doi:10.1042/BJ20100726)

Kane, N. M. et al. (2010) Lentivirus-mediated reprogramming of somatic cells in the absence of transgenic transcription factors. Molecular Therapy, 18(12), pp. 2139-2145. (doi:10.1038/mt.2010.231)

Greig, J.A., Shirley, R., Graham, D., Denby, L., Dominiczak, A.F., Work, L.M., and Baker, A. (2010) Vascular-targeting anti-oxidant therapy in a model of hypertension and stroke. Journal of Cardiovascular Pharmacology, 56(6), pp. 642-650. (doi:10.1097/FJC.0b013e3181f8f19f)

Othman, M. et al. (2010) Functional characterization of a 13-bp deletion (c.-1522_-1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand disease. Blood, 116(18), pp. 3645-3652. (doi:10.1182/blood-2009-12-261131)

Alba, R. et al. (2010) Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood, 14(116), pp. 2656-2664. (doi:10.1182/blood-2009-12-260026)

Burton, P. et al. (2010) Identification and characterization of small-molecule ligands that maintain pluripotency of human embryonic stem cells. Biochemical Society Transactions, 38(4), pp. 1058-1061. (doi:10.1042/BST0381058)

Kane, N. M., Meloni, M., Spencer, H. L., Craig, M. A., Strehl, R., Milligan, G., Houslay, M. D., Mountford, J. C., Emanueli, C., and Baker, A. H. (2010) Derivation of endothelial cells from human embryonic stem cells by directed differentiation: analysis of microRNA and angiogenesis in vitro and in vivo. Arteriosclerosis, Thrombosis and Vascular Biology, 30(7), pp. 1389-1397. (doi:10.1161/ATVBAHA.110.204800)

Craig, M. A., McBride, M. W., Smith, G., George, S., and Baker, A. (2010) Dysregulation of cadherins in the intercalated disc of the spontaneously hypertensive stroke-prone rat. Journal of Molecular and Cellular Cardiology, 48(6), pp. 1121-1128. (doi:10.1016/j.yjmcc.2010.01.017)

Caruso, P. et al. (2010) Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline. Arteriosclerosis, Thrombosis and Vascular Biology, 30(4), pp. 716-723. (doi:10.1161/ATVBAHA.109.202028)

Shin, S.Y., Kim, J.H., Baker, A.H., Lim, Y., and Lee, Y.H. (2010) Transcription factor Egr-1 is essential for maximal matrix metalloproteinase-9 transcription by tumor necrosis factor α. Molecular Cancer Research, 8(4), pp. 507-519. (doi:10.1158/1541-7786.MCR-09-0454) (PMID:20332214)

Balestrieri, M. L. et al. (2010) Therapeutic angiogenesis in diabetic apolipoprotein E-deficient mice using bone marrow cells, functional hemangioblasts and metabolic intervention. Atherosclerosis, 209(2), pp. 403-414. (doi:10.1016/j.atherosclerosis.2009.10.022)

Bradshaw, A.C., Parker, A.L., Duffy, M.R., Coughlan, L., van Rooijen, N., Kahari, V.M., Nicklin, S.A., and Baker, A.H. (2010) Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X. PLoS Pathogens, 6(10), e1001142. (doi:10.1371/journal.ppat.1001142)

Coughlan, L., Alba, R., Parker, A.L., Bradshaw, A.C., Mcneish, I.A., Nicklin, S., and Baker, A. (2010) Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses, 2(10), pp. 2290-2355. (doi:10.3390/v2102290)

Kallio, J.P., Hopkins-Donaldson, S., Baker, A.H., and Kähäri, V.M. (2010) TIMP-3 promotes apoptosis in nonadherent small cell lung carcinoma cells lacking functional death receptor pathway. International Journal of Cancer, 128(4), pp. 991-996. (doi:10.1002/ijc.25404)

Padmanabhan, S. et al. (2010) Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension. PLoS Genetics, 6(10), e1001177. (doi:10.1371/journal.pgen.1001177)

2009

Alba, R. et al. (2009) Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood, 114(5), pp. 965-971. (doi:10.1182/blood-2009-03-208835)

Terashima, T., Oka, K., Kritz, A. B., Kojima, H., Baker, A. H., and Chan, L. (2009) DRG-targeted helper-dependent adenoviruses mediate selective gene delivery for therapeutic rescue of sensory neuronopathies in mice. Journal of Clinical Investigation, 119(7), pp. 2100-2112. (doi:10.1172/JCI39038)

Nicol, C. G., Denby, L., Lopez-Franco, O., Masson, R., Halliday, C. A., Nicklin, S. A., Kritz, A., Work, L. M., and Baker, A. H. (2009) Use of in vivo phage display to engineer novel adenoviruses for targeted delivery to the cardiac vasculature. FEBS Letters, 583(12), pp. 2100-2107. (doi:10.1016/j.febslet.2009.05.037)

Diaconu, I. et al. (2009) Serotype chimeric and fiber-mutated adenovirus Ad5/19p-HIT for targeting renal cancer and untargeting the liver. Human Gene Therapy, 20(6), pp. 611-620. (doi:10.1089/hum.2008.108)

Liu, Y., Wang, H.J., Yumul, R., Gao, W.T., Gambotto, A., Morita, T., Baker, A.H., Shayakhmetov, D., and Lieber, A. (2009) Transduction of liver metastases after intravenous injection of Ad5/35 or Ad35 vectors with and without factor X-binding protein pretreatment. Human Gene Therapy, 20(6), pp. 621-629. (doi:10.1089/hum.2008.142)

Parker, A.L., Waddington, S.N., Buckley, S.M.K., Custers, J., Havenga, M.J.E., van Rooijen, N., Goudsmit, J., Mcvey, J.H., Nicklin, S.A., and Baker, A.H. (2009) Effect of neutralizing sera on factor X-mediated adenovirus serotype 5 gene transfer. Journal of Virology, 83(1), pp. 479-483. (doi:10.1128/JVI.01878-08)

Greig, J.A. et al. (2009) Influence of Coagulation Factor X on In Vitro and In Vivo Gene Delivery by Adenovirus (Ad) 5, Ad35, and Chimeric Ad5/Ad35 Vectors. Molecular Therapy, 17(10), pp. 1683-1691. (doi:10.1038/mt.2009.152)

Lenaerts, L., Mcvey, J., Baker, A., Denby, L., Nicklin, S., Verbeken, E., and Naesens, L. (2009) Mouse adenovirus type 1 and human adenovirus type 5 differ in endothelial cell tropism and liver targeting. Journal of Gene Medicine, 11(2), pp. 119-127. (doi:10.1002/jgm.1283)

Masson, R. et al. (2009) Onset of experimental severe cardiac fibrosis is mediated by overexpression of angiotensin-converting enzyme 2. Hypertension, 53(4), pp. 694-700. (doi:10.1161/HYPERTENSIONAHA.108.122333)

2008

Parker, A.L., Nicklin, S.A., and Baker, A.H. (2008) Interactions of adenovirus vectors with blood: implications for intravascular gene therapy applications. Current Opinion in Molecular Therapeutics, 10(5), pp. 439-448.

Graham, T., McIntosh, J., Work, L., Nathwani, A., and Baker, A. (2008) Performance of AAV8 vectors expressing human factor IX from a hepatic-selective promoter following intravenous injection into rats. Genetic Vaccines and Therapy, 6(1), p. 9. (doi:10.1186/1479-0556-6-9)

White, K. et al. (2008) Engineering adeno-associated virus 2 vectors for targeted gene delivery to atherosclerotic lesions. Gene Therapy, 15(6), pp. 443-451. (doi:10.1038/sj.gt.3303077)

Waddington, S. et al. (2008) Adenovirus serotype 5 hexon mediates liver gene transfer. Cell, 132(3), pp. 397-409. (doi:10.1016/j.cell.2008.01.016)

Miller, A. M., Xu, D., Asquith, D. L., Denby, L., Li, Y., Sattar, N., Baker, A. H., McInnes, I. B., and Liew, F. Y. (2008) IL-33 reduces the development of atherosclerosis. Journal of Experimental Medicine, 205(2), pp. 339-346. (doi:10.1084/jem.20071868) (PMID:18268038) (PMCID:PMC2271006)

Baker, A. (2008) Interaction of Ad5 with blood coagulation factor X mediates liver gene transfer. Human Gene Therapy, 19(10), pp. 1072-1073.

Benest, A.V., Stone, O.A., Miller, W.H., Glover, C.P., Uney, J.B., Baker, A.H., Harper, S.J., and Bates, D.O. (2008) Arteriolar genesis and angiogenesis induced by endothelial nitric oxide synthase overexpression results in a mature vasculature. Arteriosclerosis, Thrombosis and Vascular Biology, 28(8), pp. 1462-1468. (doi:10.1161/ATVBAHA.108.169375)

Buckley, S. et al. (2008) Luciferin Detection After Intranasal Vector Delivery Is Improved by Intranasal Rather Than Intraperitoneal Luciferin Administration. Human Gene Therapy, 19(10), pp. 1050-1056.

Flores-Munoz, M., Baker, A., and Nicklin, S. (2008) Development of a gene transfer vector expressing angiotensin 1-7 and assessment of its effects on cardiac hypertrophy. Journal of Human Hypertension, 22(10), p. 723.

Kane, N.M., McRae, S., Denning, C., and Baker, A.H. (2008) Viral and non-viral gene delivery and its role in pluripotent stem cell engineering. Drug Discovery Today: Technologies, 5(4), e107-e115. (doi:10.1016/j.ddtec.2008.10.002)

Kritz Wilson, A.B., Yu, J., Wright, P.L., Wan, S., George, S.J., Halliday, C., Kang, N., Sessa, W.C., and Baker, A.H. (2008) In Vivo Modulation of Nogo-B Attenuates Neointima Formation. Molecular Therapy, 16(11), pp. 1798-1804. (doi:10.1038/mt.2008.188)

Nicklin, S., and Baker, A. (2008) Efficient Vascular Endothelial Gene Transfer Following Intravenous Adenovirus Delivery. Molecular Therapy, 16(12), pp. 1904-1905. (doi:10.1038/mt.2008.226)

Parker, A., Parker, A., Mcvey, J., Waddington, S., Buckley, S., Francischetti, I., Monteiro, R., Nicklin, S., and Baker, A. (2008) An exosite within the human FX serine protease domain mediates cell transduction of AD5: FX complexes. Human Gene Therapy, 19(4), p. 34.

Wang, H. et al. (2008) In Vitro and In Vivo Properties of Adenovirus Vectors with Increased Affinity to CD46. Journal of Virology, 82(21), pp. 10567-10579.

2007

Waddington, S.N., Parker, A.L., Havenga, M., Nicklin, S.A., Buckley, S.M., McVey, J.H., and Baker, A.H. (2007) Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo: Fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5. Journal of Virology, 81(17), pp. 9568-9571. (doi:10.1128/JVI.00663-07)

Kritz, A. B., Nicol, C. G., Dishart, K. L., Nelson, R., Holbeck, S., Von Seggern, D. J., Work, L. M., Mcvey, J. H., Nicklin, S. A., and Baker, A. H. (2007) Adenovirus 5 fibers mutated at the putative HSPG-binding site show restricted retargeting with targeting peptides in the HI loop. Molecular Therapy, 15, pp. 741-749. (doi:10.1038/sj.mt.6300094)

Baker, A.H. et al. (2007) Brain protection using autologous bone marrow cell, metalloproteinase inhibitors, and metabolic treatment in cerebral ischemia. Proceedings of the National Academy of Sciences of the United States of America, 104, pp. 3597-3602. (doi:10.1073/pnas.0611112104)

Baker, A., Mcvey, J., Waddington, S., Di Paolo, N., and Shayakhmetov, D. (2007) The influence of blood on in vivo adenovirus bio-distribution and transduction. Molecular Therapy, 15(8), pp. 1410-1416. (doi:10.1038/sj.mt.6300206)

Denby, L., Work, L.M., Von Seggern, D.J., Wu, E., Mcvey, J.H., Nicklin, S.A., and Baker, A.H. (2007) Development of renal-targeted vectors through combined in vivo phage display and capsid engineering of adenoviral fibers from serotype 19p. Molecular Therapy, 15(9), pp. 1647-1654. (doi:10.1038/sj.mt.6300214)

Maffia, P., Zinselmeyer, B.H., Ialenti, A., Kennedy, S., Baker, A.H., McInnes, I., Brewer, J.M., and Garside, P. (2007) Multiphoton microscopy for 3-dimensional imaging of lymphocyte recruitment into apolipoprotein-E-deficient mouse carotid artery. Circulation, 115(11), E326-E328. (doi:10.1161/CIRCULATIONAHA.106.658492) (PMID:17372180)

Magnoni, S., Baker, A., Thomson, S., Jordan, G., George, S., Mccoll, B., McCulloch, J., and Horsburgh, K. (2007) Neuroprotective effect of adenoviral-mediated gene transfer of TIMP-1 and-2 in ischemic brain injury. Gene Therapy, 14, pp. 621-625. (doi:10.1038/sj.gt.3302894)

Mccoll, B., McGregor, A., Wong, A., Harris, J., Amalfitano, A., Magnoni, S., Baker, A., Dickson, G., and Horsburgh, K. (2007) APOE epsilon 3 gene transfer attenuates brain damage after experimental stroke. Journal of Cerebral Blood Flow and Metabolism, 27, pp. 477-487. (doi:10.1038/sj.jcbfm.9600361)

Parker, A., Mcvey, J., Doctor, J., Lopez-Franco, O., Waddington, S., Havenga, M., Nicklin, S., and Baker, A. (2007) Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from subgroup D. Journal of Virology, 81, pp. 3627-3631. (doi:10.1128/JVI.02786-06)

Sithu, S., English, W., Olson, P., Krubasik, D., Baker, A., Murphy, G., and D'Souza, S. (2007) Membrane-type 1-matrix metalloproteinase regulates intracellular adhesion molecule-1 (ICAM-1)-mediated monocyte transmigration. Journal of Biological Chemistry, 282, pp. 25010-25019. (doi:10.1074/jbc.M611273200)

Smyth, A., Reid, H., Baker, A., and McGlynn, H. (2007) Modifications of the radiosensitivity of a renal cancer cell line as a consequence of stable TIMP-1 overexpression. International Journal of Radiation Biology, 83, pp. 13-25. (doi:10.1080/09553000600983136)

Toriseva, M., Ala-aho, R., Karvinen, J., Baker, A., Marjomaki, V., Heino, J., and Kahari, V. (2007) Collagenase-3 (MMP-13) enhances remodeling of three-dimensional collagen and promotes survival of human skin fibroblasts. Journal of Investigative Dermatology, 127, pp. 49-59.

Van Roy, M., Wielockx, B., Baker, A., and Libert, C. (2007) The use of tissue inhibitors of matrix metalloproteinases to increase the efficacy of a tumor necrosis factor/interferon gamma antitumor therapy. Cancer Gene Therapy, 14, pp. 372-379. (doi:10.1038/sj.cgt.7701020)

White, K., Nicklin, S., and Baker, A. (2007) Novel vectors for in vivo gene delivery to vascular tissue. Expert Opinion on Biological Therapy, 7(6), pp. 809-821. (doi:10.1517/14712598.7.6.809)

Yoshida, S. et al. (2007) Metalloproteinase inhibition has differential effects on alloimmunity, autoimmunity, and histopathology in the transplanted lung. Transplantation, 83(6), pp. 799-808. (doi:10.1097/01.tp.0000258600.05531.5d)

2006

Parker, A.L. et al. (2006) Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes in vitro and in vivo. Blood, 108(8), pp. 2554-2561. (doi:10.1182/blood-2006-04-008532)

Perabo, L. et al. (2006) Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism. Journal of Virology, 80(14), pp. 7265-7269. (doi:10.1128/JVI.00076-06)

Baker, A., Yim, A., and Wan, S. (2006) Opportunities for gene therapy in preventing vein graft failure after coronary artery bypass surgery. Diabetes Obesity and Metabolism, 8, pp. 119-124. (doi:10.1111/j.1463-1326.2005.00494.x)

Finan, K., Hodge, G., Reynolds, A., Hodge, S., Holmes, M., Baker, A., and Reynolds, P. (2006) In vitro susceptibility to the pro-apoptotic effects of TIMP-3 gene delivery translates to greater in vivo efficacy versus gene delivery for TIMPs-1 or-2. Lung Cancer, 53, pp. 273-284. (doi:10.1016/j.lungcan.2006.06.006)

George, S., Channon, K., and Baker, A. (2006) Gene therapy and coronary artery bypass grafting: Current perspectives. Current Opinion in Molecular Therapeutics, 8, pp. 288-294.

Heymans, S. et al. (2006) Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis. Circulation, 114, pp. 565-573. (doi:10.1161/CIRCULATIONAHA.105.591032)

Johnson, J., Baker, A., Oka, K., Chan, L., Newby, A., Jackson, C., and George, S. (2006) Suppression of atherosclerotic plaque progression and instability by tissue inhibitor of metalloproteinase-2 - Involvement of macrophage migration and apoptosis. Circulation, 113, pp. 2435-2444. (doi:10.1161/CIRCULATIONAHA.106.613281)

Kim, M., Bodenstine, T., Sumerel, L., Rivera, A., Baker, A., and Douglas, J. (2006) Tissue inhibitor of metalloproteinases-2 improves antitumor efficacy of a replicating adenovirus in vivo. Cancer Biology and Therapy, 5, pp. 1647-1653.

Parker, A. et al. (2006) Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood, 108, pp. 2554-2561. (doi:10.1182/blood-2006-04-008532)

Work, L.M. et al. (2006) Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses. Molecular Therapy, 13(4), pp. 683-693. (doi:10.1016/j.ymthe.2005.11.013)

de Nooijer, R., Verkleij, C.J.N., der Thusen, J.H., Jukema, J.W., van der Wall, E.E., van Berkel, T.J.C., Baker, A.H., and Biessen, E.A.L. (2006) Lesional overexpression of matrix metalloproteinase-9 promotes intraplaque hemorrhage in advanced lesions but not at earlier stages of atherogenesis. Arteriosclerosis, Thrombosis and Vascular Biology, 26, pp. 340-346. (doi:10.1161/01.ATV.0000197795.56960.64)

2005

Akowuah, E. et al. (2005) Ultrasound-mediated delivery of TIMP-3 plasmid DNA into saphenous vein leads to increased lumen size in a porcine interposition graft model. Gene Therapy, 12, pp. 1154-1157. (doi:10.1038/sj.gt.3302498)

Baker, A., Kritz, A., Work, L., Nicklin, S., and Nicklin, A. (2005) Cell-selective viral gene delivery vectors for the vasculature. Experimental Physiology, 90(1), pp. 27-31. (doi:10.1113/expphysiol.2004.028126)

Denby, L., Nicklin, S.A., and Baker, A.H. (2005) Adeno-associated virus (AAV)-7 and-8 poorly transduce vascular endothelial cells and are sensitive to proteasomal degradation. Gene Therapy, 12, pp. 1534-1538. (doi:10.1038/sj.gt.3302564)

Heymans, S., Lupu, F., Terclavers, S., Vanwetswinkel, B., Herbert, J., Baker, A., Collen, D., Carmeliet, P., and Moons, L. (2005) Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. American Journal of Pathology, 166(1), pp. 15-25.

Lovelock, J.D., Baker, A.H., Gao, F., Dong, J.F., Bergeron, A.L., McPheat, W., Sivasubramanian, N., and Mann, D.L. (2005) Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts. American Journal of Physiology: Heart and Circulatory Physiology, 288, H461-H468. (doi:10.1152/ajpheart.00402.2004)

Miller, W., Brosnan, M.J., Graham, D., Nicol, C.G., Morecroft, I., Channon, K.M., Danilov, S.M., Reynolds, P.N., Baker, A.H., and Dominiczak, A.F. (2005) Targeting endothelial cells with adenovirus expressing nitric oxide synthase prevents elevation of blood pressure in stroke-prone spontaneously hypertensive rats. Molecular Therapy, 12(2), pp. 321-327. (doi:10.1016/j.ymthe.2005.02.025)

Miller, W.H., Nicklin, S.A., Baker, A.H., and Dominiczak, A. (2005) Gene transfer and the cardiovascular system. In: Raizada, M.K., Paton, J.F.R., Kasparov, S. and Katovich, M.J. (eds.) Cardiovascular Genomics. Series: Contemporary cardiology. Humana Press: Totowa, NJ, USA, pp. 175-196. ISBN 9781588294005

Nicklin, S., Wu, E., Nemerow, G., and Baker, A. (2005) The influence of adenovirus fiber structure and function on vector development for gene therapy. Molecular Therapy, 12(3), pp. 384-393. (doi:10.1016/j.ymthe.2005.05.008)

Parker, A., Fisher, K., Oupicky, D., Read, M., Nicklin, S., Baker, A., and Seymour, L. (2005) Enhanced gene transfer activity of peptide-targeted gene-delivery vectors. Journal of Drug Targeting, 13, pp. 39-51. (doi:10.1080/10611860400020449)

White, S., Simmonds, R., Lane, D., and Baker, A. (2005) Efficient isolation of peptide ligands for the endothelial cell protein C receptor (EPCR) using candidate receptor phage display biopanning. Peptides, 26, pp. 1264-1269. (doi:10.1016/j.peptides.2005.01.015)

2004

Work, L.M., Reynolds, P. N., and Baker, A. H. (2004) Improved gene delivery to human saphenous vein cells and tissue using a peptide-modified adenoviral vector. Genetic Vaccines and Therapy, 2(1), p. 14. (doi:10.1186/1479-0556-2-14)

Baker, A. (2004) Designing gene delivery vectors for cardiovascular gene therapy. Progress in Biophysics and Molecular Biology, 84, pp. 279-299. (doi:10.1016/j.pbiomolbio.2003.11.006)

Denby, L., Work, L.M., Graham, D., Hsu, C., Von Seggern, D.J., Nicklin, S.A., and Baker, A.H. (2004) Adenoviral serotype 5 vectors pseudotyped with fibers from subgroup D show modified tropism in vitro and in vivo. Human Gene Therapy, 15(11), pp. 1054-1064.

Elezkurtaj, S., Kopitz, C., Baker, A., Perez-Canto, A., Arlt, M., Khokha, R., Gansbacher, B., Anton, M., Brand, K., and Kruger, A. (2004) Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinases-1 in the liver: efficient protection against T-cell lymphoma and colon carcinoma metastasis. Journal of Gene Medicine, 6, pp. 1228-1237. (doi:10.1002/jgm.637)

Magnoni, S., Baker, A., George, S., Duncan, W., Kerr, L., McCulloch, J., and Horsburgh, K. (2004) Differential alterations in the expression and activity of matrix metalloproteinases 2 and 9 after transient cerebral ischemia in mice. Neurobiology of Disease, 17, pp. 188-197. (doi:10.1016/j.nbd.2004.07.020)

Nicklin, S., White, S., Nicol, C., Von Seggern, D., and Baker, A. (2004) In vitro and in vivo characterisation of endothelial cell selective adenoviral vectors. Journal of Gene Medicine, 6, pp. 300-308. (doi:10.1002/jgm.526)

Nicol, C., Graham, D., Miller, W., White, S., Smith, T., Nicklin, S., Stevenson, S., and Baker, A. (2004) Effect of adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats. Molecular Therapy, 10(2), pp. 344-354. (doi:10.1016/j.ymthe.2004.05.020)

Papadakis, E., Nicklin, S., Baker, A., and White, S. (2004) Promoters and control elements: Designing expression cassettes for gene therapy. Current Gene Therapy, 4, pp. 89-113.

Wan, S., George, S., Nicklin, S., Yim, A., and Baker, A. (2004) Overexpression of p53 increases lumen size and blocks neointima formation in porcine interposition vein grafts. Molecular Therapy, 9(5), pp. 689-698. (doi:10.1016/j.ymthe.2004.02.005)

White, S., Nicklin, S., Buning, H., Brosnan, M., Leike, K., Papadakis, E., Hallek, M., and Baker, A. (2004) Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors. Circulation, 109, pp. 513-519. (doi:10.1161/01.CIR.0000109697.68832.5D)

Work, L.M., Nicol, C.G., Denby, L., and Baker, A.H. (2004) In vivo biopanning: a methodological approach to identifying novel targeting ligands for delivery of biological agents to the vasculature. In: Fennell, J.P. and Baker, A.H. (eds.) Hypertension: Methods and Protocols. Series: Methods in molecular medicine (108). Humana Press: Totowa, NJ, USA, pp. 395-413. ISBN 9781588293237 (doi:10.1385/1-59259-850-1:395)

Work, L., Nicklin, S., Brain, N., Dishart, K., Von Seggern, D., Hallek, M., Buning, H., and Baker, A. (2004) Development of efficient viral vectors selective for vascular smooth muscle cells. Molecular Therapy, 9(2), pp. 198-208. (doi:10.1016/j.ymthe.2003.11.006)

Work, L., Ritchie, N., Nicklin, S., Reynolds, P., and Baker, A. (2004) Dual targeting of gene delivery by genetic modification of adenovirus serotype 5 fibers and cell-selective transcriptional control. Gene Therapy, 11, pp. 1296-1300. (doi:10.1038/sj.gt.3302292)

2003

Dishart, K.L., Work, L.M., Denby, L., and Baker, A.H. (2003) Gene therapy for cardiovascular disease. Journal of Biomedicine and Biotechnology, 2003(2), pp. 138-148. (doi:10.1155/S1110724303209086)

Ahonen, M., Poukkula, M., Baker, A., Kashiwagi, M., Nagase, H., Eriksson, J., and Kahari, V. (2003) Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors. Oncogene, 22, pp. 2121-2134. (doi:10.1038/sj.onc.1206292)

Baker, A. (2003) Targeting AAV vectors. Molecular Therapy, 7(4), pp. 433-434. (doi:10.1016/S1525-0016(03)00072-8)

Buning, H., Nicklin, S., Perabo, L., Hallek, M., and Baker, A. (2003) AAV-based gene transfer. Current Opinion in Molecular Therapeutics, 5, pp. 367-375.

Dishart, K.L. et al. (2003) Third-generation lentivirus vectors efficiently transduce and phenotypically modify vascular cells: implications for gene therapy. Journal of Molecular and Cellular Cardiology, 35(7), pp. 739-748. (doi:10.1016/S0022-2828(03)00136-6)

Gruss, C. et al. (2003) Stroma formation and angiogenesis by overexpression of growth factors, cytokines, and proteolytic enzymes in human skin grafted to SCID mice. Journal of Investigative Dermatology, 120, pp. 683-692.

Lambert, V. et al. (2003) MMP-2 and MMP-9 synergize in promoting choroidal neovascularization. FASEB Journal, 17(15), pp. 2290-2292. (doi:10.1096/fj.03-0113fje)

MacKenzie, C., Paul, A., Wilson, S., de Martin, R., Baker, A., and Plevin, R. (2003) Enhancement of lipopolysaccharide-stimulated JNK activity in rat aortic smooth muscle cells by pharmacological and adenovirusmediated inhibition of inhibitory kappa B kinase signalling. British Journal of Pharmacology, 139, pp. 1041-1049. (doi:10.1038/sj.bjp.0705330)

Nicklin, S.A., and Baker, A.H. (2003) Development of targeted viral vectors for cardiovascular gene therapy. In: Setlow, J.K. (ed.) Genetic Engineering, Principles and Methods. Kluwer Academic: Dordrecht, The Netherlands, pp. 15-49. ISBN 9780306477768

Nicklin, S., Dishart, K., Buening, H., Reynolds, P., Hallek, M., Nemerow, G., Von Seggern, D., and Baker, A. (2003) Transductional and transcriptional targeting of cancer cells using genetically engineered viral vectors. Cancer Letters, 201, pp. 165-173. (doi:10.1016/j.canlet.2003.07.003)

Qi, J., Ebrahem, Q., Moore, N., Murphy, G., Claesson-Welsh, L., Bond, M., Baker, A., and Anand-Apte, B. (2003) A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nature Medicine, 9, pp. 407-415. (doi:10.1038/nm846)

Tan, H., Heywood, D., Ralph, G., Bienemann, A., Baker, A., and Uney, J. (2003) Tissue inhibitor of metalloproteinase 1 inhibits excitotoxic cell death in neurons. Molecular and Cellular Neuroscience, 22, pp. 98-106. (doi:10.1016/S1044-7431(02)00024-6)

Vieillard-Baron, A., Frisdal, E., Raffestin, B., Baker, A., Eddahibi, S., Adnot, S., and D'Ortho, M. (2003) Inhibition of matrix metalloproteinases by lung TIMP-1 gene transfer limits monocrotaline-induced pulmonary vascular remodeling in rats. Human Gene Therapy, 14, pp. 861-869.

Work, L., Nicklin, S., and Baker, A. (2003) Targeting Gene Therapy Vectors to the Vascular Endothelium. Current Atherosclerosis Reports, 5(3), pp. 163-170.

de Nigris, F., Lerman, A., Ignarro, L., Williams-Ignarro, S., Sica, V., Baker, A., Lerman, L., Geng, Y., and Napoli, C. (2003) Oxidation-sensitive mechanisms, vascular apoptosis and atherosclerosis. Trends in Molecular Medicine, 9, pp. 351-359. (doi:10.1016/S1471-4914(03)00139-4)

2002

Majid, M. A., Smith, V. A., Easty, D. L., Baker, A. H., and Newby, A. C. (2002) Sorsby's fundus dystrophy mutant tissue inhibitors of metalloproteinase-3 induce apoptosis of retinal pigment epithelial and MCF-7 cells. FEBS Letters, 529(2-3), pp. 281-285. (doi:10.1016/S0014-5793(02)03359-8)

Ahonen, M., Ala-aho, R., Baker, A., George, S., Grenman, R., Saarialho-Kere, U., and Kahari, V. (2002) Antitumor activity and bystander effect of adenovirally delivered tissue inhibitor of metalloproteinases-3. Molecular Therapy, 5(6), pp. 705-715. (doi:10.1006/mthe.2002.0606)

Ala-aho, R., Johansson, N., Baker, A., and Kahari, V. (2002) Expression of collagenase-3 (MMP-13) enhances invasion of human fibrosarcoma HT-1080 cells. International Journal of Cancer, 97(3), pp. 283-289. (doi:10.1002/ijc.1619)

Bainbridge, J., Mistry, A., De Alwis, M., Paleolog, E., Baker, A., Thrasher, A., and Ali, R. (2002) Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1. Gene Therapy, 9, pp. 320-326. (doi:10.1038/sj/gt/3301680)

Baker, A. (2002) Development and use of gene transfer for treatment of cardiovascular disease. Journal of Cardiac Surgery, 17(6), pp. 543-548. (doi:10.1046/j.1540-8191.2002.01011.x)

Baker, A. (2002) Gene therapy for bypass graft failure and restenosis. Pathophysiology of Haemostasis and Thrombosis, 32, pp. 389-391.

Baker, A., Edwards, D., and Murphy, G. (2002) Metalloproteinase inhibitors: biological actions and therapeutic opportunities. Journal of Cell Science, 115, pp. 3719-3727. (doi:10.1242/jcs.00063)

Bauerschmitz, G., Nettelbeck, D., Kanerva, A., Baker, A., Hemminki, A., Reynolds, P., and Curiel, D. (2002) The flt-1 promoter for transcriptional targeting of teratocarcinoma. Cancer Research, 62, pp. 1271-1274.

Bond, M., Murphy, G., Bennett, M., Newby, A., and Baker, A. (2002) Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domain-dependent type II apoptotic pathway. Journal of Biological Chemistry, 277, pp. 13787-13795. (doi:10.1074/jbc.M111507200)

Fennell, J., Brosnan, M., Frater, A., Hamilton, C., Alexander, M., Nicklin, S., Heistad, D., Baker, A., and Dominiczak, A. (2002) Adenovirus-mediated overexpression of extracellular superoxide dismutase improves endothelial dysfunction in a rat model of hypertension. Gene Therapy, 9(2), pp. 110-117. (doi:10.1038/sj.gt.3301633)

Majid, M., Smith, V., Easty, D., Baker, A., and Newby, A. (2002) Adenovirus mediated gene delivery of tissue inhibitor of metalloproteinases-3 induces death in retinal pigment epithelial cells. British Journal of Ophthalmology, 86(1), pp. 97-101.

Nicklin, S., and Baker, A. (2002) Tropism-Modified Adenoviral and Adeno-Associated Viral Vectors for Gene Therapy. Current Gene Therapy, 2(3), pp. 273-293.

Turunen, M. et al. (2002) Peptide-retargeted adenovirus encoding a tissue inhibitor of metalloproteinase-1 decreases restenosis after intravascular gene transfer. Molecular Therapy, 6(3), pp. 306-312. (doi:10.1006/mthe.2002.0668)

Van de Louw, A., Jean, D., Frisdal, E., Cerf, C., D'Ortho, M., Baker, A., Lafuma, C., Duvaldestin, P., Harf, A., and Delclaux, C. (2002) Neutrophil proteinases in hydrochloric acid- and endotoxin-induced acute lung injury: Evaluation of interstitial protease activity by in situ zymography. Laboratory Investigation, 82, pp. 133-145.

Work, L.M., Nicklin, S.A., White, S.J., and Baker, A.H. (2002) Use of phage display to identify novel peptides for targeted gene therapy. Methods in Enzymology, 346, pp. 157-176. (doi:10.1016/S0076-6879(02)46055-7)

2001

Apparailly, F., Noel, D., Millet, V., Baker, A., Lisignoli, G., Jacquet, C., Kaiser, M., Sany, J., and Jorgensen, C. (2001) Paradoxical effects of tissue inhibitor of metalloproteinases 1 gene transfer in collagen-induced arthritis. Arthritis and Rheumatism, 44(6), pp. 1444-1454. (doi:10.1002/1529-0131(200106)44:6<1444::AID-ART240>3.0.CO;2-Q)

Bond, M., Chase, A., Baker, A., and Newby, A. (2001) Inhibition of transcription factor NF-kappa B reduces matrix metalloproteinase-1,-3 and-9 production by vascular smooth muscle cells. Cardiovascular Research, 50, pp. 556-565. (doi:10.1016/S0008-6363(01)00220-6)

George, S., Angelini, G., Capogrossi, M., and Baker, A. (2001) Wild-type p53 gene transfer inhibits neointima formation in human saphenous vein by modulation of smooth muscle cell migration and induction of apoptosis. Gene Therapy, 8(9), pp. 668-676. (doi:10.1038/sj.gt.3301431)

Hu, Y.H., Baker, A.H., Zou, Y.P., Newby, A.C., and Xu, Q.B. (2001) Local gene transfer of tissue inhibitor of metalloproteinase-2 influences vein graft remodeling in a mouse model. Arteriosclerosis, Thrombosis and Vascular Biology, 21(8), pp. 1275-1280. (doi:10.1161/hq0801.093658)

Nicklin, S., Buening, H., Dishart, K., De Alwis, M., Girod, A., Hacker, U., Thrasher, A., Ali, R., Hallek, M., and Baker, A. (2001) Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Molecular Therapy, 4(2), pp. 174-181. (doi:10.1006/mthe.2001.0424)

Nicklin, S., Reynolds, P., Brosnan, M., White, S., Curiel, D., Dominiczak, A., and Baker, A. (2001) Analysis of cell-specific promoters for viral gene therapy targeted at the vascular endothelium. Hypertension, 38(1), pp. 65-70. (doi:10.1161/01.HYP.38.1.65)

Nicklin, S., Von Seggern, D., Work, L., Pek, D., Dominiczak, A., Nemerow, G., and Baker, A. (2001) Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus. Molecular Therapy, 4(6), pp. 534-542. (doi:10.1006/mthe.2001.0489)

Reynolds, P., Nicklin, S., Kaliberova, L., Boatman, B., Grizzle, W., Balyasnikova, I., Baker, A., Danilov, S., and Curiel, D. (2001) Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nature Biotechnology, 19, pp. 838-842.

White, S., Nicklin, S., Sawamura, T., and Baker, A. (2001) Identification of peptides that target the endothelial cell-specific LOX-1 receptor. Hypertension, 37, pp. 449-455.

2000

Bond, M., Murphy, G., Bennett, M., Amour, A., Knauper, V., Newby, A., and Baker, A. (2000) Localization of the death domain of tissue inhibitor of metalloproteinase-3 to the N terminus - Metalloproteinase inhibition is associated with proapoptotic activity. Journal of Biological Chemistry, 275(52), pp. 41358-41363. (doi:10.1074/jbc.M007929200)

This list was generated on Wed Jun 29 15:36:41 2016 BST.
Number of items: 191.

Articles

Ballantyne, M.D., McDonald, R.A., and Baker, A.H. (2016) lncRNA/MicroRNA interactions in the vasculature. Clinical Pharmacology and Therapeutics, 99(5), pp. 494-501. (doi:10.1002/cpt.355) (PMID:26910520)

Boulberdaa, M. et al. (2016) A role for the long non-coding RNA SENCR in commitment and function of endothelial cells. Molecular Therapy, 24(5), pp. 978-990. (doi:10.1038/mt.2016.41) (PMID:26898221)

Stevens, H. C., Deng, L., Grant, J. S., Pinel, K., Thomas, M., Morrell, N. W., MacLean, M. R., and Baker, A. (2016) Regulation and function of miR-214 in pulmonary arterial hypertension. Pulmonary Circulation, 6(1), pp. 109-117. (doi:10.1086/685079)

Alonso-Padilla, J., Papp, T., Kaján, G. L., Benkő, M., Havenga, M., Lemckert, A., Harrach, B., and Baker, A. H. (2016) Development of novel adenoviral vectors to overcome challenges observed with HAdV-5 based constructs. Molecular Therapy, (doi:10.1038/mt.2015.194) (PMID:26478249)

Brittan, M., Hunter, A., Boulberdaa, M., Fujisawa, T., Skinner, E. M., Shah, A. S., Baker, A.H., and Mills, N. L. (2015) Impaired vascular function and repair in patients with premature coronary artery disease. European Journal of Preventive Cardiology, 22(12), pp. 1557-1566. (doi:10.1177/2047487315600169) (PMID:26276790)

Deng, L. et al. (2015) MicroRNA-143 activation regulates smooth muscle and endothelial cell crosstalk in pulmonary arterial hypertension. Circulation Research, 117(10), pp. 870-883. (doi:10.1161/CIRCRESAHA.115.306806) (PMID:26311719)

McDonald, R. A., Pinel, K., and Baker, A. H. (2015) Micro(RNA) management of smooth muscle cell phenotype and response to vascular injury. Cardiovascular Research, 107(4), pp. 403-406. (doi:10.1093/cvr/cvv199) (PMID:26224571)

Schneider, M. D., Baker, A. H., and Riley, P. (2015) Hopx and the cardiomyocyte parentage. Molecular Therapy, 23(9), pp. 1420-1422. (doi:10.1038/mt.2015.140) (PMID:26321185)

Wallace, E., Morrell, N. W., Yang, X. D., Long, L., Stevens, H., Nilsen, M., Loughlin, L., Mair, K. M., Baker, A. H., and MacLean, M. R. (2015) A sex-specific microRNA-96/5HT1B Axis influences development of pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine, 191(12), pp. 1432-1442. (doi:10.1164/rccm.201412-2148OC) (PMID:25871906)

McDonald, R. A. et al. (2015) Reducing in-stent restenosis therapeutic manipulation of miRNA in vascular remodeling and inflammation. Journal of the American College of Cardiology, 65(21), pp. 2314-2327. (doi:10.1016/j.jacc.2015.03.549) (PMID:26022821) (PMCID:PMC4444526)

Dakin, R. S., Parker, A. L., Delles, C., Nicklin, S. A., and Baker, A. H. (2015) Efficient transduction of primary vascular cells by the rare adenovirus serotype 49 vector. Human Gene Therapy, 26(5), pp. 312-319. (doi:10.1089/hum.2015.019) (PMID:25760682)

Nicklin, S. A., Griesenbach, U., and Baker, A. H. (2015) Special focus issue on the annual meeting of the british society for gene and cell therapy. Human Gene Therapy, 26(5), pp. 247-248. (doi:10.1089/hum.2015.2500) (PMID:25989311)

Duffy, M., Ma, J., Deng, L., Dakin, R. S., Uil, T., Custers, J., Kelly, S. M., McVey, J. H., Nicklin, S. A., and Baker, A. H. (2015) Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivo. PLoS Pathogens, 11(2), e1004673. (doi:10.1371/journal.ppat.1004673)

Lopez Gordo, E., Denby, L., Nicklin, S. A., and Baker, A. H. (2014) The importance of coagulation factors binding to adenovirus: historical perspectives and implications for gene delivery. Expert Opinion on Drug Delivery, 11(11), pp. 1795-1813. (doi:10.1517/17425247.2014.938637)

White, K. et al. (2014) Endothelial apoptosis in pulmonary hypertension is controlled by a microRNA/programmed cell death 4/caspase-3 axis. Hypertension, 64(1), pp. 185-194. (doi:10.1161/HYPERTENSIONAHA.113.03037)

Coughlan, L., Uusi-Kerttula, H., Ma, J., Degg, B. P., Parker, A. L., and Baker, A. H. (2014) Retargeting adenovirus serotype 48 fiber knob domain by peptide incorporation. Human Gene Therapy, 25(4), pp. 385-394. (doi:10.1089/hum.2014.016) (PMID:24617540)

Baker, A. H. (2014) Adenovirus-based vectors: maximizing opportunities and optimizing a rich diversity of vectors for gene-based therapy. Human Gene Therapy, 25(4), pp. 255-256. (doi:10.1089/hum.2014.2508)

Denby, L. et al. (2014) MicroRNA-214 antagonism protects against renal fibrosis. Journal of the American Society of Nephrology, 25(1), pp. 65-80. (doi:10.1681/ASN.2013010072)

Grant, J. S., Morecroft, I., Dempsie, Y., van Rooij, E., MacLean, M. R., and Baker, A. H. (2013) Transient but not genetic loss of miR-451 attenuates the development of pulmonary arterial hypertension. Pulmonary Circulation, 3(4), pp. 840-850. (doi:10.1086/674751) (PMID:25006399) (PMCID:PMC4070830)

Grant, J. S., White, K., MacLean, M. R., and Baker, A. H. (2013) MicroRNAs in pulmonary arterial remodeling. Cellular and Molecular Life Sciences, 70(23), pp. 4479-4494. (doi:10.1007/s00018-013-1382-5)

Ramdas, V., McBride, M., Denby, L., and Baker, A. H. (2013) Canonical transforming growth factor-β signaling regulates disintegrin metalloprotease expression in experimental renal fibrosis via miR-29. American Journal of Pathology, 183(6), pp. 1885-1896. (doi:10.1016/j.ajpath.2013.08.027)

Scott, E., Loya, K., Mountford, J., Milligan, G., and Baker, A. H. (2013) MicroRNA regulation of endothelial homeostasis and commitment—implications for vascular regeneration strategies using stem cell therapies. Free Radical Biology and Medicine, 64, pp. 52-60. (doi:10.1016/j.freeradbiomed.2013.04.037)

Duffy, M. R., Parker, A. L., Kalkman, E. R., White, K., Kovalskyy, D., Kelly, S. M., and Baker, A. H. (2013) Identification of novel small molecule inhibitors of adenovirus gene transfer using a high throughput screening approach. Journal of Controlled Release, 170(1), pp. 132-140. (doi:10.1016/j.jconrel.2013.05.007)

McDonald, R. A. et al. (2013) miRNA-21 is dysregulated in response to vein grafting in multiple models and genetic ablation in mice attenuates neointima formation. European Heart Journal, 34(22), pp. 1636-1643. (doi:10.1093/eurheartj/eht105)

Baker, A.H., Nicklin, S.A., and Shayakhmetov, D.M. (2013) FX and host defense evasion tactics by adenovirus. Molecular Therapy, 21(6), pp. 1109-1111. (doi:10.1038/mt.2013.100)

McKimmie, C.S. et al. (2013) An analysis of the function and expression of D6 on lymphatic endothelial cells. Blood, 121(18), pp. 3768-3777. (doi:10.1182/blood-2012-04-425314)

Baker, A. H., and Delles, C. (2013) Is microRNA-376c a biomarker or mediator of preeclampsia? Hypertension, 61(4), pp. 767-769. (doi:10.1161/HYPERTENSIONAHA.111.00087)

Bradshaw, A. C., and Baker, A. H. (2013) Gene therapy for cardiovascular disease: perspectives and potential. Vascular Pharmacology, 58(3), pp. 174-181. (doi:10.1016/j.vph.2012.10.008)

Howard, L., Mackenzie, R. M., Pchelintsev, N. A., McBryan, T., McClure, J. D., McBride, M. W., Kane, N. M., Adams, P. D., Milligan, G., and Baker, A. H. (2013) Profiling of transcriptional and epigenetic changes during directed endothelial differentiation of human embryonic stem cells identifies FOXA2 as a marker of early mesoderm commitment. Stem Cell Research and Therapy, 4(2), Art. 36. (doi:10.1186/scrt192)

Kane, N., and Baker, A. (2013) Pluripotent stem cell-derived endothelial cells for vascular disease therapy. International Drug Discovery, (In Press)

Parker, A.L., White, K.M., Lavery, C.A., Custers, J., Waddington, S.N., and Baker, A.H. (2013) Pseudotyping the adenovirus serotype 5 capsid with both the fibre and penton of serotype 35 enhances vascular smooth muscle cell transduction. Gene Therapy, 20(12), pp. 1158-1164. (doi:10.1038/gt.2013.44)

Son, D.J. et al. (2013) The atypical mechanosensitive microRNA-712 derived from pre-ribosomal RNA induces endothelial inflammation and atherosclerosis. Nature Communications, 4(3000), (doi:10.1038/ncomms4000)

White, K. M., Alba, R., Parker, A. L., Wright, A. F., Bradshaw, A. C., Delles, C., McDonald, R. A., and Baker, A. H. (2013) Assessment of a novel, capsid-modified adenovirus with an improved vascular gene transfer profile. Journal of Cardiothoracic Surgery, 8(183), (doi:10.1186/1749-8090-8-183)

Bradshaw, A. C., Coughlan, L., Miller, A. M.., Nicklin, S. A., Baker, A. H., Alba, R., and van Rooijen, N. (2012) Biodistribution and inflammatory profiles of novel penton and hexon double-mutant serotype 5 adenoviruses. Journal of Controlled Release, 164(3), pp. 394-402. (doi:10.1016/j.jconrel.2012.05.025)

Miller, A. M., Xu, D., Asquith, D. L., Denby, L., Li, Y., Sattar, N., Baker, A. H., McInnes, I. B., and Liew, F. Y. (2012) IL-33 reduces the development of atherosclerosis (vol 205, pg 339, 2008). Journal of Experimental Medicine, 209(13), p. 2515. (doi:10.1084/jem.2007186820913c)

Coughlan, L. et al. (2012) Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery. Molecular Therapy, 20(12), pp. 2268-2281. (doi:10.1038/mt.2012.162)

Chick, H.E. et al. (2012) Integrase-deficient lentiviral vectors mediate efficient gene transfer to human vascular smooth muscle cells with minimal genotoxic risk. Human Gene Therapy, 23(12), pp. 1247-1257. (doi:10.1089/hum.2012.042)

Kaupisch, A., Kennedy, L., Stelmanis, V., Tye, B., Kane, N.M., Mountford, J.C., Courtney, A., and Baker, A.H. (2012) Derivation of vascular endothelial cells from human embryonic stem cells under GMP-compliant conditions: towards clinical studies in ischaemic disease. Journal of Cardiovascular Translational Research, 5(5), pp. 605-617. (doi:10.1007/s12265-012-9379-2)

Robinson, H. C., and Baker, A. H. (2012) How do microRNAs affect vascular smooth muscle cell biology? Current Opinion in Lipidology, 23(5), pp. 405-411. (doi:10.1097/MOL.0b013e32835719a1)

Robertson, K.E., McDonald, R.A., Oldroyd, K.G., Nicklin, S.A., and Baker, A.H. (2012) Prevention of coronary in-stent restenosis and vein graft failure: Does vascular gene therapy have a role? Pharmacology and Therapeutics, 136(1), pp. 23-34. (doi:10.1016/j.pharmthera.2012.07.002)

Coughlan, L., Vallath, S., Gros, A., Giménez-Alejandre, M., Van Rooijen, N., Thomas, G.J., Baker, A.H., Cascalló, M., Alemany, R., and Hart, I.R. (2012) Combined fiber modifications both to target αvβ6 and detarget the coxsackievirus–adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5. Human Gene Therapy, 23(9), pp. 960-979. (doi:10.1089/hum.2011.218)

Caruso, P. et al. (2012) A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples. Circulation Research, 111(3), pp. 290-300. (doi:10.1161/CIRCRESAHA.112.267591)

Baker, A.H. (2012) Spotlight: Andrew Baker, PhD, FAHA, FESC, FRSE: "A strategy of short-term genetic engineering prevented long-term pathological processes in the vein graft". Circulation, 125(21), F121-F123. (doi:10.1161/CIR.0b013e31825e771f)

Kane, N. M. et al. (2012) Role of MicroRNAs 99b, 181a, and 181b in the differentiation of human embryonic stem cells to vascular endothelial cells. Stem Cells, 30(4), pp. 643-654. (doi:10.1002/stem.1026)

White, K., Kane, N. M., Milligan, G., and Baker, A. H. (2012) The role of miRNA in stem cell pluripotency and commitment to the vascular endothelial lineage. Microcirculation, 19(3), pp. 196-207. (doi:10.1111/j.1549-8719.2012.00161.x)

McDonald, R. A., Hata, A., MacLean, M. R., Morrell, N. W., and Baker, A. H. (2012) MicroRNA and vascular remodelling in acute vascular injury and pulmonary vascular remodelling. Cardiovascular Research, 93(4), pp. 594-604. (doi:10.1093/cvr/cvr299)

Duffy, M. R., Parker, A. L., Bradshaw, A. C., and Baker, A. H. (2012) Manipulation of adenovirus interactions with host factors for gene therapy applications. Nanomedicine, 7(2), pp. 271-288. (doi:10.2217/nnm.11.186)

Alba, R., Bradshaw, A.C., Mestre-Francés, N., Verdier, J.-M., Henaff, D., and Baker, A.H. (2012) Coagulation factor X mediates adenovirus type 5 liver gene transfer in non-human primates (Microcebus murinus). Gene Therapy, 19(1), pp. 109-113. (doi:10.1038/gt.2011.87)

Coughlan, L., Vallath, S., Gros, A., Giménez-Alejandre, M., Van Rooijen, N., Thomas, G.J., Baker, A.H., Cascalló, M., Alemany, R., and Hart, I.R. (2012) Combined fiber modifications both to target αvβ6 and detarget the coxsackievirus–adenovirus receptor improve virus toxicity profilesIn vivobut fail to improve antitumoral efficacy relative to adenovirus serotype 5. Human Gene Therapy, 23(9), pp. 960-979. (doi:10.1089/hum.2011.218)

Duffy, M.R., Kalkman, E., and Baker, A.H. (2012) Identification of a novel small molecule inhibitor of FX-mediated Ad5 gene transfer for gene therapy applications. Molecular Therapy, 20(S1), S117-S117. (doi:10.1038/mt.2012.86)

Flores, M., Graham, D., Dominiczak, A.F., Milligan, G., Baker, A.H., and Nicklin, S.A. (2012) Angiotensin-(1-9) antagonises Angiotensin II-induced cardiac remodeling via the angiotensin type 2 receptor. Proceedings of the Physiological Society, 27, C1.

Flores, M., Graham, D., Dominiczak, A. F., Milligan, G., Baker, A. H., and Nicklin, S. A. (2012) Abstract 231: angiotensin-(1-9) antagonises cardiac remodelling in a mouse model of Angiotensin Ii-induced hypertension. Hypertension, 60, A231.

Morecroft, I., White, K., Caruso, P., Nilsen, M., Loughlin, L., Alba, R., Reynolds, P.N., Danilov, S.M., Baker, A.H., and MacLean, M.R. (2012) Gene therapy by targeted adenovirus-mediated knockdown of pulmonary endothelial Tph1 attenuates hypoxia-induced pulmonary hypertension. Molecular Therapy, 20(8), pp. 1516-1528. (doi:10.1038/mt.2012.70)

Rahim, A.A. et al. (2012) In utero administration of Ad5 and AAV pseudotypes to the fetal brain leads to efficient, widespread and long-term gene expression. Gene Therapy, 19(9), pp. 936-946. (doi:10.1038/gt.2011.157)

Ialenti, A. et al. (2011) Inhibition of in-stent stenosis by oral administration of bindarit in porcine coronary arteries. Arteriosclerosis, Thrombosis and Vascular Biology, 31(11), pp. 2448-2454. (doi:10.1161/ATVBAHA.111.230078)

Howard, L., Kane, N., Milligan, G., and Baker, A. H. (2011) MicroRNAs regulating cell pluripotency and vascular differentiation. Vascular Pharmacology, 55(4), pp. 69-78. (doi:10.1016/j.vph.2011.08.002)

Duffy, M.R., Bradshaw, A.C., Parker, A.L., McVey, J.H., and Baker, A.H. (2011) A cluster of basic amino acids in the factor X serine protease mediate surface attachment of adenovirus/FX complexes. Journal of Virology, 85(20), pp. 10914-10919. (doi:10.1128/JVI.05382-11)

White, K., Loughlin, L., Maqbool, Z., Nilsen, M., McClure, J., Dempsie, Y., Baker, A. H., and MacLean, M. R. (2011) Serotonin transporter, sex, and hypoxia: microarray analysis in the pulmonary arteries of mice identifies genes with relevance to human PAH. Physiological Genomics, 43(8), pp. 417-437. (doi:10.1152/physiolgenomics.00249.2010)

Caporali, A. et al. (2011) Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation, 123(3), pp. 282-291. (doi:10.1161/CIRCULATIONAHA.110.952325)

Kane, N. M., Xiao, Q., Baker, A. H., Luo, Z., Xu, Q., and Emanueli, C. (2011) Pluripotent stem cell differentiation into vascular cells: a novel technology with promises for vascular re(generation). Pharmacology and Therapeutics, 129(1), pp. 29-49. (doi:10.1016/j.pharmthera.2010.10.004)

Baker, A.H. (2011) MicroRNA 21 "Shapes" Vascular Smooth Muscle Behavior Through Regulating Tropomyosin 1. Arteriosclerosis, Thrombosis and Vascular Biology, 31(9), pp. 1941-1942. (doi:10.1161/ATVBAHA.111.231985)

Denby, L. et al. (2011) miR-21 and miR-214 are consistently modulated during renal injury in rodent models. American Journal of Pathology, 179(2), pp. 661-672. (doi:10.1016/j.ajpath.2011.04.021)

George, S. J., Wan, S., Hu, J., McDonald, R.A., Johnson, J. L., and Baker, A.H. (2011) Sustained reduction of vein graft neointima formation by ex vivo TIMP-3 gene therapy. Circulation, 124(11_sup), S135-S142. (doi:10.1161/CIRCULATIONAHA.110.012732)

Burton, P. et al. (2010) Erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) blocks differentiation and maintains the expression of pluripotency markers in human embryonic stem cells. Biochemical Journal, 432(3), pp. 575-584. (doi:10.1042/BJ20100726)

Kane, N. M. et al. (2010) Lentivirus-mediated reprogramming of somatic cells in the absence of transgenic transcription factors. Molecular Therapy, 18(12), pp. 2139-2145. (doi:10.1038/mt.2010.231)

Greig, J.A., Shirley, R., Graham, D., Denby, L., Dominiczak, A.F., Work, L.M., and Baker, A. (2010) Vascular-targeting anti-oxidant therapy in a model of hypertension and stroke. Journal of Cardiovascular Pharmacology, 56(6), pp. 642-650. (doi:10.1097/FJC.0b013e3181f8f19f)

Othman, M. et al. (2010) Functional characterization of a 13-bp deletion (c.-1522_-1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand disease. Blood, 116(18), pp. 3645-3652. (doi:10.1182/blood-2009-12-261131)

Alba, R. et al. (2010) Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood, 14(116), pp. 2656-2664. (doi:10.1182/blood-2009-12-260026)

Burton, P. et al. (2010) Identification and characterization of small-molecule ligands that maintain pluripotency of human embryonic stem cells. Biochemical Society Transactions, 38(4), pp. 1058-1061. (doi:10.1042/BST0381058)

Kane, N. M., Meloni, M., Spencer, H. L., Craig, M. A., Strehl, R., Milligan, G., Houslay, M. D., Mountford, J. C., Emanueli, C., and Baker, A. H. (2010) Derivation of endothelial cells from human embryonic stem cells by directed differentiation: analysis of microRNA and angiogenesis in vitro and in vivo. Arteriosclerosis, Thrombosis and Vascular Biology, 30(7), pp. 1389-1397. (doi:10.1161/ATVBAHA.110.204800)

Craig, M. A., McBride, M. W., Smith, G., George, S., and Baker, A. (2010) Dysregulation of cadherins in the intercalated disc of the spontaneously hypertensive stroke-prone rat. Journal of Molecular and Cellular Cardiology, 48(6), pp. 1121-1128. (doi:10.1016/j.yjmcc.2010.01.017)

Caruso, P. et al. (2010) Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline. Arteriosclerosis, Thrombosis and Vascular Biology, 30(4), pp. 716-723. (doi:10.1161/ATVBAHA.109.202028)

Shin, S.Y., Kim, J.H., Baker, A.H., Lim, Y., and Lee, Y.H. (2010) Transcription factor Egr-1 is essential for maximal matrix metalloproteinase-9 transcription by tumor necrosis factor α. Molecular Cancer Research, 8(4), pp. 507-519. (doi:10.1158/1541-7786.MCR-09-0454) (PMID:20332214)

Balestrieri, M. L. et al. (2010) Therapeutic angiogenesis in diabetic apolipoprotein E-deficient mice using bone marrow cells, functional hemangioblasts and metabolic intervention. Atherosclerosis, 209(2), pp. 403-414. (doi:10.1016/j.atherosclerosis.2009.10.022)

Bradshaw, A.C., Parker, A.L., Duffy, M.R., Coughlan, L., van Rooijen, N., Kahari, V.M., Nicklin, S.A., and Baker, A.H. (2010) Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X. PLoS Pathogens, 6(10), e1001142. (doi:10.1371/journal.ppat.1001142)

Coughlan, L., Alba, R., Parker, A.L., Bradshaw, A.C., Mcneish, I.A., Nicklin, S., and Baker, A. (2010) Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses, 2(10), pp. 2290-2355. (doi:10.3390/v2102290)

Kallio, J.P., Hopkins-Donaldson, S., Baker, A.H., and Kähäri, V.M. (2010) TIMP-3 promotes apoptosis in nonadherent small cell lung carcinoma cells lacking functional death receptor pathway. International Journal of Cancer, 128(4), pp. 991-996. (doi:10.1002/ijc.25404)

Padmanabhan, S. et al. (2010) Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension. PLoS Genetics, 6(10), e1001177. (doi:10.1371/journal.pgen.1001177)

Alba, R. et al. (2009) Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood, 114(5), pp. 965-971. (doi:10.1182/blood-2009-03-208835)

Terashima, T., Oka, K., Kritz, A. B., Kojima, H., Baker, A. H., and Chan, L. (2009) DRG-targeted helper-dependent adenoviruses mediate selective gene delivery for therapeutic rescue of sensory neuronopathies in mice. Journal of Clinical Investigation, 119(7), pp. 2100-2112. (doi:10.1172/JCI39038)

Nicol, C. G., Denby, L., Lopez-Franco, O., Masson, R., Halliday, C. A., Nicklin, S. A., Kritz, A., Work, L. M., and Baker, A. H. (2009) Use of in vivo phage display to engineer novel adenoviruses for targeted delivery to the cardiac vasculature. FEBS Letters, 583(12), pp. 2100-2107. (doi:10.1016/j.febslet.2009.05.037)

Diaconu, I. et al. (2009) Serotype chimeric and fiber-mutated adenovirus Ad5/19p-HIT for targeting renal cancer and untargeting the liver. Human Gene Therapy, 20(6), pp. 611-620. (doi:10.1089/hum.2008.108)

Liu, Y., Wang, H.J., Yumul, R., Gao, W.T., Gambotto, A., Morita, T., Baker, A.H., Shayakhmetov, D., and Lieber, A. (2009) Transduction of liver metastases after intravenous injection of Ad5/35 or Ad35 vectors with and without factor X-binding protein pretreatment. Human Gene Therapy, 20(6), pp. 621-629. (doi:10.1089/hum.2008.142)

Parker, A.L., Waddington, S.N., Buckley, S.M.K., Custers, J., Havenga, M.J.E., van Rooijen, N., Goudsmit, J., Mcvey, J.H., Nicklin, S.A., and Baker, A.H. (2009) Effect of neutralizing sera on factor X-mediated adenovirus serotype 5 gene transfer. Journal of Virology, 83(1), pp. 479-483. (doi:10.1128/JVI.01878-08)

Greig, J.A. et al. (2009) Influence of Coagulation Factor X on In Vitro and In Vivo Gene Delivery by Adenovirus (Ad) 5, Ad35, and Chimeric Ad5/Ad35 Vectors. Molecular Therapy, 17(10), pp. 1683-1691. (doi:10.1038/mt.2009.152)

Lenaerts, L., Mcvey, J., Baker, A., Denby, L., Nicklin, S., Verbeken, E., and Naesens, L. (2009) Mouse adenovirus type 1 and human adenovirus type 5 differ in endothelial cell tropism and liver targeting. Journal of Gene Medicine, 11(2), pp. 119-127. (doi:10.1002/jgm.1283)

Masson, R. et al. (2009) Onset of experimental severe cardiac fibrosis is mediated by overexpression of angiotensin-converting enzyme 2. Hypertension, 53(4), pp. 694-700. (doi:10.1161/HYPERTENSIONAHA.108.122333)

Parker, A.L., Nicklin, S.A., and Baker, A.H. (2008) Interactions of adenovirus vectors with blood: implications for intravascular gene therapy applications. Current Opinion in Molecular Therapeutics, 10(5), pp. 439-448.

Graham, T., McIntosh, J., Work, L., Nathwani, A., and Baker, A. (2008) Performance of AAV8 vectors expressing human factor IX from a hepatic-selective promoter following intravenous injection into rats. Genetic Vaccines and Therapy, 6(1), p. 9. (doi:10.1186/1479-0556-6-9)

White, K. et al. (2008) Engineering adeno-associated virus 2 vectors for targeted gene delivery to atherosclerotic lesions. Gene Therapy, 15(6), pp. 443-451. (doi:10.1038/sj.gt.3303077)

Waddington, S. et al. (2008) Adenovirus serotype 5 hexon mediates liver gene transfer. Cell, 132(3), pp. 397-409. (doi:10.1016/j.cell.2008.01.016)

Miller, A. M., Xu, D., Asquith, D. L., Denby, L., Li, Y., Sattar, N., Baker, A. H., McInnes, I. B., and Liew, F. Y. (2008) IL-33 reduces the development of atherosclerosis. Journal of Experimental Medicine, 205(2), pp. 339-346. (doi:10.1084/jem.20071868) (PMID:18268038) (PMCID:PMC2271006)

Baker, A. (2008) Interaction of Ad5 with blood coagulation factor X mediates liver gene transfer. Human Gene Therapy, 19(10), pp. 1072-1073.

Benest, A.V., Stone, O.A., Miller, W.H., Glover, C.P., Uney, J.B., Baker, A.H., Harper, S.J., and Bates, D.O. (2008) Arteriolar genesis and angiogenesis induced by endothelial nitric oxide synthase overexpression results in a mature vasculature. Arteriosclerosis, Thrombosis and Vascular Biology, 28(8), pp. 1462-1468. (doi:10.1161/ATVBAHA.108.169375)

Buckley, S. et al. (2008) Luciferin Detection After Intranasal Vector Delivery Is Improved by Intranasal Rather Than Intraperitoneal Luciferin Administration. Human Gene Therapy, 19(10), pp. 1050-1056.

Flores-Munoz, M., Baker, A., and Nicklin, S. (2008) Development of a gene transfer vector expressing angiotensin 1-7 and assessment of its effects on cardiac hypertrophy. Journal of Human Hypertension, 22(10), p. 723.

Kane, N.M., McRae, S., Denning, C., and Baker, A.H. (2008) Viral and non-viral gene delivery and its role in pluripotent stem cell engineering. Drug Discovery Today: Technologies, 5(4), e107-e115. (doi:10.1016/j.ddtec.2008.10.002)

Kritz Wilson, A.B., Yu, J., Wright, P.L., Wan, S., George, S.J., Halliday, C., Kang, N., Sessa, W.C., and Baker, A.H. (2008) In Vivo Modulation of Nogo-B Attenuates Neointima Formation. Molecular Therapy, 16(11), pp. 1798-1804. (doi:10.1038/mt.2008.188)

Nicklin, S., and Baker, A. (2008) Efficient Vascular Endothelial Gene Transfer Following Intravenous Adenovirus Delivery. Molecular Therapy, 16(12), pp. 1904-1905. (doi:10.1038/mt.2008.226)

Parker, A., Parker, A., Mcvey, J., Waddington, S., Buckley, S., Francischetti, I., Monteiro, R., Nicklin, S., and Baker, A. (2008) An exosite within the human FX serine protease domain mediates cell transduction of AD5: FX complexes. Human Gene Therapy, 19(4), p. 34.

Wang, H. et al. (2008) In Vitro and In Vivo Properties of Adenovirus Vectors with Increased Affinity to CD46. Journal of Virology, 82(21), pp. 10567-10579.

Waddington, S.N., Parker, A.L., Havenga, M., Nicklin, S.A., Buckley, S.M., McVey, J.H., and Baker, A.H. (2007) Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo: Fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5. Journal of Virology, 81(17), pp. 9568-9571. (doi:10.1128/JVI.00663-07)

Kritz, A. B., Nicol, C. G., Dishart, K. L., Nelson, R., Holbeck, S., Von Seggern, D. J., Work, L. M., Mcvey, J. H., Nicklin, S. A., and Baker, A. H. (2007) Adenovirus 5 fibers mutated at the putative HSPG-binding site show restricted retargeting with targeting peptides in the HI loop. Molecular Therapy, 15, pp. 741-749. (doi:10.1038/sj.mt.6300094)

Baker, A.H. et al. (2007) Brain protection using autologous bone marrow cell, metalloproteinase inhibitors, and metabolic treatment in cerebral ischemia. Proceedings of the National Academy of Sciences of the United States of America, 104, pp. 3597-3602. (doi:10.1073/pnas.0611112104)

Baker, A., Mcvey, J., Waddington, S., Di Paolo, N., and Shayakhmetov, D. (2007) The influence of blood on in vivo adenovirus bio-distribution and transduction. Molecular Therapy, 15(8), pp. 1410-1416. (doi:10.1038/sj.mt.6300206)

Denby, L., Work, L.M., Von Seggern, D.J., Wu, E., Mcvey, J.H., Nicklin, S.A., and Baker, A.H. (2007) Development of renal-targeted vectors through combined in vivo phage display and capsid engineering of adenoviral fibers from serotype 19p. Molecular Therapy, 15(9), pp. 1647-1654. (doi:10.1038/sj.mt.6300214)

Maffia, P., Zinselmeyer, B.H., Ialenti, A., Kennedy, S., Baker, A.H., McInnes, I., Brewer, J.M., and Garside, P. (2007) Multiphoton microscopy for 3-dimensional imaging of lymphocyte recruitment into apolipoprotein-E-deficient mouse carotid artery. Circulation, 115(11), E326-E328. (doi:10.1161/CIRCULATIONAHA.106.658492) (PMID:17372180)

Magnoni, S., Baker, A., Thomson, S., Jordan, G., George, S., Mccoll, B., McCulloch, J., and Horsburgh, K. (2007) Neuroprotective effect of adenoviral-mediated gene transfer of TIMP-1 and-2 in ischemic brain injury. Gene Therapy, 14, pp. 621-625. (doi:10.1038/sj.gt.3302894)

Mccoll, B., McGregor, A., Wong, A., Harris, J., Amalfitano, A., Magnoni, S., Baker, A., Dickson, G., and Horsburgh, K. (2007) APOE epsilon 3 gene transfer attenuates brain damage after experimental stroke. Journal of Cerebral Blood Flow and Metabolism, 27, pp. 477-487. (doi:10.1038/sj.jcbfm.9600361)

Parker, A., Mcvey, J., Doctor, J., Lopez-Franco, O., Waddington, S., Havenga, M., Nicklin, S., and Baker, A. (2007) Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from subgroup D. Journal of Virology, 81, pp. 3627-3631. (doi:10.1128/JVI.02786-06)

Sithu, S., English, W., Olson, P., Krubasik, D., Baker, A., Murphy, G., and D'Souza, S. (2007) Membrane-type 1-matrix metalloproteinase regulates intracellular adhesion molecule-1 (ICAM-1)-mediated monocyte transmigration. Journal of Biological Chemistry, 282, pp. 25010-25019. (doi:10.1074/jbc.M611273200)

Smyth, A., Reid, H., Baker, A., and McGlynn, H. (2007) Modifications of the radiosensitivity of a renal cancer cell line as a consequence of stable TIMP-1 overexpression. International Journal of Radiation Biology, 83, pp. 13-25. (doi:10.1080/09553000600983136)

Toriseva, M., Ala-aho, R., Karvinen, J., Baker, A., Marjomaki, V., Heino, J., and Kahari, V. (2007) Collagenase-3 (MMP-13) enhances remodeling of three-dimensional collagen and promotes survival of human skin fibroblasts. Journal of Investigative Dermatology, 127, pp. 49-59.

Van Roy, M., Wielockx, B., Baker, A., and Libert, C. (2007) The use of tissue inhibitors of matrix metalloproteinases to increase the efficacy of a tumor necrosis factor/interferon gamma antitumor therapy. Cancer Gene Therapy, 14, pp. 372-379. (doi:10.1038/sj.cgt.7701020)

White, K., Nicklin, S., and Baker, A. (2007) Novel vectors for in vivo gene delivery to vascular tissue. Expert Opinion on Biological Therapy, 7(6), pp. 809-821. (doi:10.1517/14712598.7.6.809)

Yoshida, S. et al. (2007) Metalloproteinase inhibition has differential effects on alloimmunity, autoimmunity, and histopathology in the transplanted lung. Transplantation, 83(6), pp. 799-808. (doi:10.1097/01.tp.0000258600.05531.5d)

Parker, A.L. et al. (2006) Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes in vitro and in vivo. Blood, 108(8), pp. 2554-2561. (doi:10.1182/blood-2006-04-008532)

Perabo, L. et al. (2006) Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism. Journal of Virology, 80(14), pp. 7265-7269. (doi:10.1128/JVI.00076-06)

Baker, A., Yim, A., and Wan, S. (2006) Opportunities for gene therapy in preventing vein graft failure after coronary artery bypass surgery. Diabetes Obesity and Metabolism, 8, pp. 119-124. (doi:10.1111/j.1463-1326.2005.00494.x)

Finan, K., Hodge, G., Reynolds, A., Hodge, S., Holmes, M., Baker, A., and Reynolds, P. (2006) In vitro susceptibility to the pro-apoptotic effects of TIMP-3 gene delivery translates to greater in vivo efficacy versus gene delivery for TIMPs-1 or-2. Lung Cancer, 53, pp. 273-284. (doi:10.1016/j.lungcan.2006.06.006)

George, S., Channon, K., and Baker, A. (2006) Gene therapy and coronary artery bypass grafting: Current perspectives. Current Opinion in Molecular Therapeutics, 8, pp. 288-294.

Heymans, S. et al. (2006) Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis. Circulation, 114, pp. 565-573. (doi:10.1161/CIRCULATIONAHA.105.591032)

Johnson, J., Baker, A., Oka, K., Chan, L., Newby, A., Jackson, C., and George, S. (2006) Suppression of atherosclerotic plaque progression and instability by tissue inhibitor of metalloproteinase-2 - Involvement of macrophage migration and apoptosis. Circulation, 113, pp. 2435-2444. (doi:10.1161/CIRCULATIONAHA.106.613281)

Kim, M., Bodenstine, T., Sumerel, L., Rivera, A., Baker, A., and Douglas, J. (2006) Tissue inhibitor of metalloproteinases-2 improves antitumor efficacy of a replicating adenovirus in vivo. Cancer Biology and Therapy, 5, pp. 1647-1653.

Parker, A. et al. (2006) Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood, 108, pp. 2554-2561. (doi:10.1182/blood-2006-04-008532)

Work, L.M. et al. (2006) Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses. Molecular Therapy, 13(4), pp. 683-693. (doi:10.1016/j.ymthe.2005.11.013)

de Nooijer, R., Verkleij, C.J.N., der Thusen, J.H., Jukema, J.W., van der Wall, E.E., van Berkel, T.J.C., Baker, A.H., and Biessen, E.A.L. (2006) Lesional overexpression of matrix metalloproteinase-9 promotes intraplaque hemorrhage in advanced lesions but not at earlier stages of atherogenesis. Arteriosclerosis, Thrombosis and Vascular Biology, 26, pp. 340-346. (doi:10.1161/01.ATV.0000197795.56960.64)

Akowuah, E. et al. (2005) Ultrasound-mediated delivery of TIMP-3 plasmid DNA into saphenous vein leads to increased lumen size in a porcine interposition graft model. Gene Therapy, 12, pp. 1154-1157. (doi:10.1038/sj.gt.3302498)

Baker, A., Kritz, A., Work, L., Nicklin, S., and Nicklin, A. (2005) Cell-selective viral gene delivery vectors for the vasculature. Experimental Physiology, 90(1), pp. 27-31. (doi:10.1113/expphysiol.2004.028126)

Denby, L., Nicklin, S.A., and Baker, A.H. (2005) Adeno-associated virus (AAV)-7 and-8 poorly transduce vascular endothelial cells and are sensitive to proteasomal degradation. Gene Therapy, 12, pp. 1534-1538. (doi:10.1038/sj.gt.3302564)

Heymans, S., Lupu, F., Terclavers, S., Vanwetswinkel, B., Herbert, J., Baker, A., Collen, D., Carmeliet, P., and Moons, L. (2005) Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. American Journal of Pathology, 166(1), pp. 15-25.

Lovelock, J.D., Baker, A.H., Gao, F., Dong, J.F., Bergeron, A.L., McPheat, W., Sivasubramanian, N., and Mann, D.L. (2005) Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts. American Journal of Physiology: Heart and Circulatory Physiology, 288, H461-H468. (doi:10.1152/ajpheart.00402.2004)

Miller, W., Brosnan, M.J., Graham, D., Nicol, C.G., Morecroft, I., Channon, K.M., Danilov, S.M., Reynolds, P.N., Baker, A.H., and Dominiczak, A.F. (2005) Targeting endothelial cells with adenovirus expressing nitric oxide synthase prevents elevation of blood pressure in stroke-prone spontaneously hypertensive rats. Molecular Therapy, 12(2), pp. 321-327. (doi:10.1016/j.ymthe.2005.02.025)

Nicklin, S., Wu, E., Nemerow, G., and Baker, A. (2005) The influence of adenovirus fiber structure and function on vector development for gene therapy. Molecular Therapy, 12(3), pp. 384-393. (doi:10.1016/j.ymthe.2005.05.008)

Parker, A., Fisher, K., Oupicky, D., Read, M., Nicklin, S., Baker, A., and Seymour, L. (2005) Enhanced gene transfer activity of peptide-targeted gene-delivery vectors. Journal of Drug Targeting, 13, pp. 39-51. (doi:10.1080/10611860400020449)

White, S., Simmonds, R., Lane, D., and Baker, A. (2005) Efficient isolation of peptide ligands for the endothelial cell protein C receptor (EPCR) using candidate receptor phage display biopanning. Peptides, 26, pp. 1264-1269. (doi:10.1016/j.peptides.2005.01.015)

Work, L.M., Reynolds, P. N., and Baker, A. H. (2004) Improved gene delivery to human saphenous vein cells and tissue using a peptide-modified adenoviral vector. Genetic Vaccines and Therapy, 2(1), p. 14. (doi:10.1186/1479-0556-2-14)

Baker, A. (2004) Designing gene delivery vectors for cardiovascular gene therapy. Progress in Biophysics and Molecular Biology, 84, pp. 279-299. (doi:10.1016/j.pbiomolbio.2003.11.006)

Denby, L., Work, L.M., Graham, D., Hsu, C., Von Seggern, D.J., Nicklin, S.A., and Baker, A.H. (2004) Adenoviral serotype 5 vectors pseudotyped with fibers from subgroup D show modified tropism in vitro and in vivo. Human Gene Therapy, 15(11), pp. 1054-1064.

Elezkurtaj, S., Kopitz, C., Baker, A., Perez-Canto, A., Arlt, M., Khokha, R., Gansbacher, B., Anton, M., Brand, K., and Kruger, A. (2004) Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinases-1 in the liver: efficient protection against T-cell lymphoma and colon carcinoma metastasis. Journal of Gene Medicine, 6, pp. 1228-1237. (doi:10.1002/jgm.637)

Magnoni, S., Baker, A., George, S., Duncan, W., Kerr, L., McCulloch, J., and Horsburgh, K. (2004) Differential alterations in the expression and activity of matrix metalloproteinases 2 and 9 after transient cerebral ischemia in mice. Neurobiology of Disease, 17, pp. 188-197. (doi:10.1016/j.nbd.2004.07.020)

Nicklin, S., White, S., Nicol, C., Von Seggern, D., and Baker, A. (2004) In vitro and in vivo characterisation of endothelial cell selective adenoviral vectors. Journal of Gene Medicine, 6, pp. 300-308. (doi:10.1002/jgm.526)

Nicol, C., Graham, D., Miller, W., White, S., Smith, T., Nicklin, S., Stevenson, S., and Baker, A. (2004) Effect of adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats. Molecular Therapy, 10(2), pp. 344-354. (doi:10.1016/j.ymthe.2004.05.020)

Papadakis, E., Nicklin, S., Baker, A., and White, S. (2004) Promoters and control elements: Designing expression cassettes for gene therapy. Current Gene Therapy, 4, pp. 89-113.

Wan, S., George, S., Nicklin, S., Yim, A., and Baker, A. (2004) Overexpression of p53 increases lumen size and blocks neointima formation in porcine interposition vein grafts. Molecular Therapy, 9(5), pp. 689-698. (doi:10.1016/j.ymthe.2004.02.005)

White, S., Nicklin, S., Buning, H., Brosnan, M., Leike, K., Papadakis, E., Hallek, M., and Baker, A. (2004) Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors. Circulation, 109, pp. 513-519. (doi:10.1161/01.CIR.0000109697.68832.5D)

Work, L., Nicklin, S., Brain, N., Dishart, K., Von Seggern, D., Hallek, M., Buning, H., and Baker, A. (2004) Development of efficient viral vectors selective for vascular smooth muscle cells. Molecular Therapy, 9(2), pp. 198-208. (doi:10.1016/j.ymthe.2003.11.006)

Work, L., Ritchie, N., Nicklin, S., Reynolds, P., and Baker, A. (2004) Dual targeting of gene delivery by genetic modification of adenovirus serotype 5 fibers and cell-selective transcriptional control. Gene Therapy, 11, pp. 1296-1300. (doi:10.1038/sj.gt.3302292)

Dishart, K.L., Work, L.M., Denby, L., and Baker, A.H. (2003) Gene therapy for cardiovascular disease. Journal of Biomedicine and Biotechnology, 2003(2), pp. 138-148. (doi:10.1155/S1110724303209086)

Ahonen, M., Poukkula, M., Baker, A., Kashiwagi, M., Nagase, H., Eriksson, J., and Kahari, V. (2003) Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors. Oncogene, 22, pp. 2121-2134. (doi:10.1038/sj.onc.1206292)

Baker, A. (2003) Targeting AAV vectors. Molecular Therapy, 7(4), pp. 433-434. (doi:10.1016/S1525-0016(03)00072-8)

Buning, H., Nicklin, S., Perabo, L., Hallek, M., and Baker, A. (2003) AAV-based gene transfer. Current Opinion in Molecular Therapeutics, 5, pp. 367-375.

Dishart, K.L. et al. (2003) Third-generation lentivirus vectors efficiently transduce and phenotypically modify vascular cells: implications for gene therapy. Journal of Molecular and Cellular Cardiology, 35(7), pp. 739-748. (doi:10.1016/S0022-2828(03)00136-6)

Gruss, C. et al. (2003) Stroma formation and angiogenesis by overexpression of growth factors, cytokines, and proteolytic enzymes in human skin grafted to SCID mice. Journal of Investigative Dermatology, 120, pp. 683-692.

Lambert, V. et al. (2003) MMP-2 and MMP-9 synergize in promoting choroidal neovascularization. FASEB Journal, 17(15), pp. 2290-2292. (doi:10.1096/fj.03-0113fje)

MacKenzie, C., Paul, A., Wilson, S., de Martin, R., Baker, A., and Plevin, R. (2003) Enhancement of lipopolysaccharide-stimulated JNK activity in rat aortic smooth muscle cells by pharmacological and adenovirusmediated inhibition of inhibitory kappa B kinase signalling. British Journal of Pharmacology, 139, pp. 1041-1049. (doi:10.1038/sj.bjp.0705330)

Nicklin, S., Dishart, K., Buening, H., Reynolds, P., Hallek, M., Nemerow, G., Von Seggern, D., and Baker, A. (2003) Transductional and transcriptional targeting of cancer cells using genetically engineered viral vectors. Cancer Letters, 201, pp. 165-173. (doi:10.1016/j.canlet.2003.07.003)

Qi, J., Ebrahem, Q., Moore, N., Murphy, G., Claesson-Welsh, L., Bond, M., Baker, A., and Anand-Apte, B. (2003) A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nature Medicine, 9, pp. 407-415. (doi:10.1038/nm846)

Tan, H., Heywood, D., Ralph, G., Bienemann, A., Baker, A., and Uney, J. (2003) Tissue inhibitor of metalloproteinase 1 inhibits excitotoxic cell death in neurons. Molecular and Cellular Neuroscience, 22, pp. 98-106. (doi:10.1016/S1044-7431(02)00024-6)

Vieillard-Baron, A., Frisdal, E., Raffestin, B., Baker, A., Eddahibi, S., Adnot, S., and D'Ortho, M. (2003) Inhibition of matrix metalloproteinases by lung TIMP-1 gene transfer limits monocrotaline-induced pulmonary vascular remodeling in rats. Human Gene Therapy, 14, pp. 861-869.

Work, L., Nicklin, S., and Baker, A. (2003) Targeting Gene Therapy Vectors to the Vascular Endothelium. Current Atherosclerosis Reports, 5(3), pp. 163-170.

de Nigris, F., Lerman, A., Ignarro, L., Williams-Ignarro, S., Sica, V., Baker, A., Lerman, L., Geng, Y., and Napoli, C. (2003) Oxidation-sensitive mechanisms, vascular apoptosis and atherosclerosis. Trends in Molecular Medicine, 9, pp. 351-359. (doi:10.1016/S1471-4914(03)00139-4)

Majid, M. A., Smith, V. A., Easty, D. L., Baker, A. H., and Newby, A. C. (2002) Sorsby's fundus dystrophy mutant tissue inhibitors of metalloproteinase-3 induce apoptosis of retinal pigment epithelial and MCF-7 cells. FEBS Letters, 529(2-3), pp. 281-285. (doi:10.1016/S0014-5793(02)03359-8)

Ahonen, M., Ala-aho, R., Baker, A., George, S., Grenman, R., Saarialho-Kere, U., and Kahari, V. (2002) Antitumor activity and bystander effect of adenovirally delivered tissue inhibitor of metalloproteinases-3. Molecular Therapy, 5(6), pp. 705-715. (doi:10.1006/mthe.2002.0606)

Ala-aho, R., Johansson, N., Baker, A., and Kahari, V. (2002) Expression of collagenase-3 (MMP-13) enhances invasion of human fibrosarcoma HT-1080 cells. International Journal of Cancer, 97(3), pp. 283-289. (doi:10.1002/ijc.1619)

Bainbridge, J., Mistry, A., De Alwis, M., Paleolog, E., Baker, A., Thrasher, A., and Ali, R. (2002) Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1. Gene Therapy, 9, pp. 320-326. (doi:10.1038/sj/gt/3301680)

Baker, A. (2002) Development and use of gene transfer for treatment of cardiovascular disease. Journal of Cardiac Surgery, 17(6), pp. 543-548. (doi:10.1046/j.1540-8191.2002.01011.x)

Baker, A. (2002) Gene therapy for bypass graft failure and restenosis. Pathophysiology of Haemostasis and Thrombosis, 32, pp. 389-391.

Baker, A., Edwards, D., and Murphy, G. (2002) Metalloproteinase inhibitors: biological actions and therapeutic opportunities. Journal of Cell Science, 115, pp. 3719-3727. (doi:10.1242/jcs.00063)

Bauerschmitz, G., Nettelbeck, D., Kanerva, A., Baker, A., Hemminki, A., Reynolds, P., and Curiel, D. (2002) The flt-1 promoter for transcriptional targeting of teratocarcinoma. Cancer Research, 62, pp. 1271-1274.

Bond, M., Murphy, G., Bennett, M., Newby, A., and Baker, A. (2002) Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domain-dependent type II apoptotic pathway. Journal of Biological Chemistry, 277, pp. 13787-13795. (doi:10.1074/jbc.M111507200)

Fennell, J., Brosnan, M., Frater, A., Hamilton, C., Alexander, M., Nicklin, S., Heistad, D., Baker, A., and Dominiczak, A. (2002) Adenovirus-mediated overexpression of extracellular superoxide dismutase improves endothelial dysfunction in a rat model of hypertension. Gene Therapy, 9(2), pp. 110-117. (doi:10.1038/sj.gt.3301633)

Majid, M., Smith, V., Easty, D., Baker, A., and Newby, A. (2002) Adenovirus mediated gene delivery of tissue inhibitor of metalloproteinases-3 induces death in retinal pigment epithelial cells. British Journal of Ophthalmology, 86(1), pp. 97-101.

Nicklin, S., and Baker, A. (2002) Tropism-Modified Adenoviral and Adeno-Associated Viral Vectors for Gene Therapy. Current Gene Therapy, 2(3), pp. 273-293.

Turunen, M. et al. (2002) Peptide-retargeted adenovirus encoding a tissue inhibitor of metalloproteinase-1 decreases restenosis after intravascular gene transfer. Molecular Therapy, 6(3), pp. 306-312. (doi:10.1006/mthe.2002.0668)

Van de Louw, A., Jean, D., Frisdal, E., Cerf, C., D'Ortho, M., Baker, A., Lafuma, C., Duvaldestin, P., Harf, A., and Delclaux, C. (2002) Neutrophil proteinases in hydrochloric acid- and endotoxin-induced acute lung injury: Evaluation of interstitial protease activity by in situ zymography. Laboratory Investigation, 82, pp. 133-145.

Work, L.M., Nicklin, S.A., White, S.J., and Baker, A.H. (2002) Use of phage display to identify novel peptides for targeted gene therapy. Methods in Enzymology, 346, pp. 157-176. (doi:10.1016/S0076-6879(02)46055-7)

Apparailly, F., Noel, D., Millet, V., Baker, A., Lisignoli, G., Jacquet, C., Kaiser, M., Sany, J., and Jorgensen, C. (2001) Paradoxical effects of tissue inhibitor of metalloproteinases 1 gene transfer in collagen-induced arthritis. Arthritis and Rheumatism, 44(6), pp. 1444-1454. (doi:10.1002/1529-0131(200106)44:6<1444::AID-ART240>3.0.CO;2-Q)

Bond, M., Chase, A., Baker, A., and Newby, A. (2001) Inhibition of transcription factor NF-kappa B reduces matrix metalloproteinase-1,-3 and-9 production by vascular smooth muscle cells. Cardiovascular Research, 50, pp. 556-565. (doi:10.1016/S0008-6363(01)00220-6)

George, S., Angelini, G., Capogrossi, M., and Baker, A. (2001) Wild-type p53 gene transfer inhibits neointima formation in human saphenous vein by modulation of smooth muscle cell migration and induction of apoptosis. Gene Therapy, 8(9), pp. 668-676. (doi:10.1038/sj.gt.3301431)

Hu, Y.H., Baker, A.H., Zou, Y.P., Newby, A.C., and Xu, Q.B. (2001) Local gene transfer of tissue inhibitor of metalloproteinase-2 influences vein graft remodeling in a mouse model. Arteriosclerosis, Thrombosis and Vascular Biology, 21(8), pp. 1275-1280. (doi:10.1161/hq0801.093658)

Nicklin, S., Buening, H., Dishart, K., De Alwis, M., Girod, A., Hacker, U., Thrasher, A., Ali, R., Hallek, M., and Baker, A. (2001) Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Molecular Therapy, 4(2), pp. 174-181. (doi:10.1006/mthe.2001.0424)

Nicklin, S., Reynolds, P., Brosnan, M., White, S., Curiel, D., Dominiczak, A., and Baker, A. (2001) Analysis of cell-specific promoters for viral gene therapy targeted at the vascular endothelium. Hypertension, 38(1), pp. 65-70. (doi:10.1161/01.HYP.38.1.65)

Nicklin, S., Von Seggern, D., Work, L., Pek, D., Dominiczak, A., Nemerow, G., and Baker, A. (2001) Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus. Molecular Therapy, 4(6), pp. 534-542. (doi:10.1006/mthe.2001.0489)

Reynolds, P., Nicklin, S., Kaliberova, L., Boatman, B., Grizzle, W., Balyasnikova, I., Baker, A., Danilov, S., and Curiel, D. (2001) Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nature Biotechnology, 19, pp. 838-842.

White, S., Nicklin, S., Sawamura, T., and Baker, A. (2001) Identification of peptides that target the endothelial cell-specific LOX-1 receptor. Hypertension, 37, pp. 449-455.

Bond, M., Murphy, G., Bennett, M., Amour, A., Knauper, V., Newby, A., and Baker, A. (2000) Localization of the death domain of tissue inhibitor of metalloproteinase-3 to the N terminus - Metalloproteinase inhibition is associated with proapoptotic activity. Journal of Biological Chemistry, 275(52), pp. 41358-41363. (doi:10.1074/jbc.M007929200)

Book Sections

Parker, A. L., Bradshaw, A. C., Alba, R., Nicklin, S. A., and Baker, A. H. (2013) Capsid modification strategies for detargeting adenoviral vectors. In: Chillon, M. and Bosch, A. (eds.) Adenovirus: Methods and Protocols [3rd.]. Series: Methods in molecular biology (1089). Humana Press, pp. 45-59. ISBN 9781627036788 (doi:10.1007/978-1-62703-679-5_3)

Miller, W.H., Nicklin, S.A., Baker, A.H., and Dominiczak, A. (2005) Gene transfer and the cardiovascular system. In: Raizada, M.K., Paton, J.F.R., Kasparov, S. and Katovich, M.J. (eds.) Cardiovascular Genomics. Series: Contemporary cardiology. Humana Press: Totowa, NJ, USA, pp. 175-196. ISBN 9781588294005

Work, L.M., Nicol, C.G., Denby, L., and Baker, A.H. (2004) In vivo biopanning: a methodological approach to identifying novel targeting ligands for delivery of biological agents to the vasculature. In: Fennell, J.P. and Baker, A.H. (eds.) Hypertension: Methods and Protocols. Series: Methods in molecular medicine (108). Humana Press: Totowa, NJ, USA, pp. 395-413. ISBN 9781588293237 (doi:10.1385/1-59259-850-1:395)

Nicklin, S.A., and Baker, A.H. (2003) Development of targeted viral vectors for cardiovascular gene therapy. In: Setlow, J.K. (ed.) Genetic Engineering, Principles and Methods. Kluwer Academic: Dordrecht, The Netherlands, pp. 15-49. ISBN 9780306477768

This list was generated on Wed Jun 29 15:36:41 2016 BST.